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ABSTRACT 
YA-WEN TENG: The Metabolic Consequences of Mouse Betaine Homocysteine S-
Methyltransferase Deficiency 
(Under the direction of Steven H. Zeisel) 
 
 
Betaine homocysteine S-methyltransferase (BHMT, EC 2.1.1.5) catalyzes the 
conversion of homocysteine to methionine. Homocysteine is a potentially harmful amino 
acid. Its elevation is often associated with cardiovascular disease, birth defect, renal 
insufficiency, and age-related cognitive impairment in humans. Humans have common single 
nucleotide polymorphisms (SNPs) in the BHMT gene that can alter its enzyme activity and 
function. Elucidation of the metabolic consequences of BHMT deficiency is critical to the 
understanding of the relationship between BHMT mutations and diseases. To directly 
investigate the role of BHMT in vivo, we generated and characterized the mice with the gene 
encoding Bhmt deleted (Bhmt-/-). This dissertation describes two separate projects. The first 
project examines the roles of BHMT in one-carbon metabolism and the development of 
hepatic steatosis and hepatocellular carcinoma. The second project examines the role of 
BHMT in energy metabolism. 
 
In the first project, we generated and characterized the Bhmt-/- mouse. We found that 
deletion of Bhmt resulted in elevated homocysteine concentrations, in reduced methylation 
potential, and in profound alterations of choline metabolites in various tissues. Bhmt-/- mice 
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developed fatty liver at five weeks of age due to reduced phosphatidylcholine concentration. 
Phosphatidylcholine is required for the synthesis of lipoproteins, which carry lipids from the 
liver to circulation. By one year of age, 64% of Bhmt-/- mice had visible hepatic tumors. 
Histopathological analysis revealed that Bhmt-/- mice developed hepatocellular carcinoma or 
carcinoma precursors.  
 
We observed that Bhmt-/- mice had reduced body weight from five to nine weeks of 
age. This observation led us to investigate the potential role of BHMT in energy metabolism. 
We found that the reduced body weight in Bhmt-/- mice was due to reduced fat mass. Bhmt-/- 
mice had smaller adipocytes, better glucose tolerance, and enhanced insulin sensitivity. 
Several factors contributed to the reduced adiposity phenotype observed in Bhmt-/- mice; 
these included increased energy expenditure, reduced mobilization of lipid from the liver to 
adipose tissue, decreased lipid synthesis within adipocytes, and enhanced whole-body 
glucose oxidation. This dissertation provides novel findings that BHMT plays critical roles in 
hepatocellular carcinoma development and energy metabolism.  
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CHAPTER I 
INTRODUCTION 
 
One-carbon metabolism is a network of interrelated biological reactions that donate, 
accept, and regenerate the one-carbon moieties (-CH3, methyl group) needed for numerous 
cellular processes. Over the past few years, one-carbon metabolism has received increasing 
attention due to its involvement in epigenetic modification and cancer risk. One-carbon 
metabolism includes both the choline and the homocysteine pathways. Betaine homocysteine 
S-methyltransferase (BHMT) is the enzyme that integrates these pathways. BHMT uses a 
methyl group from the choline-metabolite betaine to methylate homocysteine. Homocysteine 
becomes methionine, the precursor of S-adenosylmethionine that is the universal methyl 
donor for most cellular methylation processes. While the importance of one-carbon 
metabolism in human diseases is being gradually elucidated, we have very limited 
information on BHMT, a key enzyme in one-carbon metabolism. 
 
Humans have common single nucleotide polymorphisms (SNPs) in the BHMT gene 
that can alter its enzyme activity and function. SNPs are identified in several epidemiological 
studies in humans as bring associated with the altered risks of various diseases. The 
epidemiological evidence regarding the functional effects of BHMT SNPs, however, remains 
controversial. The goal of this dissertation is to elucidate the metabolic consequences of 
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BHMT deficiency in order to understand the relationship between BHMT mutations 
and diseases.  
 
To achieve this goal, we generated the mouse model with the gene encoding Bhmt 
deleted (Bhmt-/-). We found that Bhmt deficiency resulted in one-carbon metabolism 
distortion with elevated homocysteine concentrations, altered choline metabolites, and 
reduced methylation potential. Bhmt deficiency disturbed hepatic health as these mice 
developed fatty liver at five weeks of age and hepatocellular carcinoma at one year of age. 
Bhmt deficiency also affected growth. Compared to the controls, Bhmt-/- mice had reduced 
body weight, which was due to decreased fat mass. Bhmt deficiency reduced adiposity by 
increasing energy expenditure, reducing lipid mobilization from the liver to adipose tissue, 
limiting lipid synthesis within adipocytes, and enhancing whole body glucose metabolism.  
  
This dissertation affirms the critical role of BHMT in one-carbon metabolism. It also 
provides novel and convincing data that BHMT is involved in hepatocellular carcinogenesis 
and energy metabolism. Liver cancer is among one of the most lethal cancers. Fatty liver and 
obesity are highly prevalent in the United States. This work has identified a new mechanism 
potentially involved in these diseases.       
 
Specific Aims: 
1. Generate the mouse with the gene encoding Bhmt deleted globally. 
2. Determine the role of Bhmt deficiency in one-carbon metabolism and in hepatic 
health. 
 
3. Determine the role of Bhmt deficiency in energy metabolism. 
  
 
 
 
 
CHAPTER II 
BACKGROUND 
 
2.1 General Aspects of Betaine Homocysteine S-Methyltransferase (BHMT) 
 
Betaine homocysteine S-methyltransferase (BHMT, EC 2.1.1.5) is a zinc-dependent 
cytosolic enzyme found in the choline oxidation pathway. BHMT catalyzes the transfer of a 
methyl group (-CH3) from betaine (also known as N,N,N-trimethylglycine or glycine betaine) 
to homocysteine (Hcy). The products of this reaction are dimethylglycine and methionine 
(Figure 2.1). This reaction follows an ordered Bi-Bi mechanism with Hcy being the first 
substrate to bind and methionine being the final product off [1, 2]. 
 
Figure 2.1 Action of BHMT. BHMT converts betaine and homocysteine to dimethylglycine 
and methionine respectively. BHMT, betaine homocysteine S-methyltransferase; Hcy, 
homocysteine; DMG, dimethylglycine. Figure from Teng Y. J. Biol. Chem. 2011; 
286(42):36258-67. 
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In mammals, BHMT protein is detected as early as day 10 of gestation [11, 12], and is 
present in adults [13].  BHMT is found in liver, kidney, brain and lenses of humans, and in 
liver and kidney of rodents [14]. It is one of the most abundant proteins in mammalian liver; 
BHMT is estimated to account for 0.6-1.6% of the total protein in the liver [14]. On the other 
hand, its activity is low in the human kidney and extremely low in the rodent kidney (Table 
2.1) [13, 15]. BHMT gene expression and BHMT activity increase when dietary choline and 
betaine are abundant, and when methionine is limited [3, 16, 17]. BHMT activity is subject to 
feedback inhibition, as it is strongly inhibited by dimethylglycine and weakly inhibited by 
methionine [2].  
 
Figure 2.2 Structure of BHMT. (a) Structure of the rat liver BHMT tetramer. The 
asymmetric unit contains four molecules. Zinc atoms are represented as grey spheres at each 
active-site. (b) Electron density map showing the three essential cysteine residues 
coordinated to the zinc atom. Figures from Evans J. Structure. 2002; 10(9), 1159-71. Gozalez 
B. J. Mol. Biol. 2004; 338, 771-782.  
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Recently, betaine homocysteine methyltransferase 2 (BHMT2, EC 2.1.1.5) has been 
identified to also methylate Hcy to methionine [18, 19]. The human BHMT2 gene is located 
22.3 kb 5’ of BHMT and encodes a protein that is 73% identical to that of BHMT. Unlike 
BHMT, BHMT2 cannot use betaine but uses S-methylmethionine (SMM) as the methyl 
donor [18, 20]. BHMT2 protein degrades rapidly unless it is bound to BHMT and stabilized 
by Hcy [18, 20]. In mouse liver, BHMT2 activity is very low, with activity less than 5% of 
that of BHMT (Table 2.1) [18]. As with BHMT, there have been low amounts of BHMT2 
activity detected in mouse kidney [18]. No BHMT2 activity has been detected in the heart, 
skeletal muscle, spleen, brain, small intestine, or lung [18]. The role and the significance of 
BHMT2 remain to be determined. 
 
Table 2.1 BHMT and BHMT2 activities in mouse liver and kidney. Table from Szegedi S. 
J. Biol. Chem. 2008; 283 (14), 8939-45. 
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2.2 Interactions of BHMT  
2.2.1 BHMT and Choline Metabolism 
 
Betaine, the methyl donor for BHMT, was first isolated from sugar beets (Beta 
vulgaris) by Scheibler, a German Chemist, in the 1860s [21, 22]. Scheibler named it 
“Betaine,” and showed that it has the structure of a trimethylglycine (Figure 2.1). Aside from 
sugar beets high levels of betaine can be found in foods such as wheat germ, shrimp, and 
spinach [23]. Betaine is rapidly absorbed in the ileum via transporters, and its bioavailability 
is assumed to be close to 100% [24]. The estimated dietary intake of betaine ranges from 
100-300 mg/day [25]. However, a recommended daily intake of betaine has not been 
established since betaine can also be produced endogenously from an essential nutrient, 
choline. Choline dehydrogenase (CHDH, EC 1.1.99.1) oxidizes choline to betaine aldehyde 
in the inner mitochondrial membrane (Figure 2.3). Betaine aldehyde dehydrogenase (BADH, 
EC 1.2.1.8) then transforms betaine aldehyde to betaine in the mitochondrial matrix [26, 27]. 
Betaine moves from mitochondria to cytosol, where BHMT is active. This movement is 
believed to be accomplished by passive diffusion as no active transport process has been 
identified. The liver and the kidney cortex are the principal sites for choline oxidation. Since 
betaine cannot be reduced back to choline, this oxidation pathway commits choline to be 
used for methylation. 
  
  
 7 
 
 
Figure 2.3 Metabolism of choline and betaine and its relationship to one-carbon 
metabolism. AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; BADH, 
betaine aldehyde dehydrogenase; Bet, betaine; BHMT, betaine homocysteine S-
methyltransferase; CCT, CTP-phosphocholine cytidylyltransferase; CHK, choline kinase; 
CHDH, choline dehydrogenase; CPT, cytidine 5-diphosphate (CDP) choline: diacylglycerol 
choline phosphotransferase; DDH, dimethylglycine dehydrogenase; DMG, dimethylglycine; 
Gly, glycine; GNMT, glycine N-methyltransferase; Hcy, homocysteine; Met, methionine; 
mTHF, 5-methyltetrahydrofolate; MTHF, methylenetetrahydrofolate; MTR, methionine 
synthase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, 
phosphatidylethanolamine N-methyltransferase; Sarc, sarcosine (monomethylglycine); SDH, 
sarcosine dehydrogenase; Ser, serine; SHMT, serine hydroxymethyltransferase; THF, 
tetrahydrofolate. Figure from Ueland P. J. Inherit. Metab. Dis. 2011; 34, 3-15. 
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Choline, the precursor of betaine, comes from the diet or de novo synthesis in tissues. 
Excellent sources of dietary choline are foods that contain membranes, such as eggs and liver. 
The recommended daily intake for choline is 550 mg/day for men and 425 mg/day for 
women [28]. Choline exists in foods as free choline or choline esters, from which choline is 
freed by pancreatic enzymes. These choline esters include phosphocholine, 
glycerophosphocholine, phosphatidylcholine (PtdCho), and sphingomyelin [26]. Choline is 
absorbed in the small intestine. Free choline enters the portal circulation and is mostly taken 
up by the liver [29], whereas lipid-soluble PtdCho and sphingomyelin enter via lymph and 
bypass the liver. Therefore, different forms of choline may have different bioavailability [30]. 
In addition, choline can be formed endogenously (mainly in the liver) by the enzyme 
phosphatidylethanolamine-N-methyltransferase (PEMT, EC 2.1.1.17). PEMT catalyzes the 
conversion of phosphatidylethanolamine (PtdEtn) to PtdCho using three S-
adenosylmethionine (AdoMet) molecules. PtdCho is either incorporated into cell membranes 
or degraded to regenerate choline through phospholipase D (EC 3.1.4.4) [31]. PtdCho serves 
as the reservoir for choline, accounting for 95% of the total choline pool in mammalian 
tissues. The remaining 5% includes choline species such as choline, phosphocholine, 
glycerophosphocholine, cytidine 5-diphosphocholine, and acetylcholine [27, 32]. 
 
Choline is a water-soluble nutrient that is often grouped with the Vitamin B complex. 
However, because it is not catalytic in function and is used as a substrate, it is not truly a 
vitamin. Choline is crucial for the normal function of all cells [26]. As mentioned above, 
choline can be converted to betaine, the carrier of methyl groups. Choline is used to form the 
neurotransmitter acetylcholine, the main mediator of the parasympathetic nervous system. 
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Choline is needed for membrane phospholipid formation. Choline enters the CDP-choline 
(Kennedy) pathway, forming phosphocholine and ultimately PtdCho (Figure 2.3 & 2.4), 
which accounts for over 50% of the phospholipids in mammalian membranes. Thereby, 
choline ensures the structural integrity and the signaling function of cell membranes [26, 33]. 
PtdCho is involved in the assembly and the secretion of the very low density lipoproteins 
(VLDLs), which export fat from the liver to circulation [26]. Choline deficient humans 
develop fatty liver [27] due to the lack of PtdCho to export triacylglycerol from the liver [34]. 
Choline deficiency in humans is also associated with liver damage [27], muscle damage [35], 
lymphocyte DNA damage and apoptosis [36] and elevated plasma Hcy after a methionine 
load [37].  
 
As mentioned before, PtdCho can also be formed by the action of PEMT from PtdEtn 
in three steps using AdoMet molecules as the methyl donors [38]. The PEMT pathway 
generates approximately 30% of the PtdCho in the liver, while the CDP-choline pathway 
generates the other 70%  [39]. Mice that lack the Pemt gene develop fatty liver and severe 
liver damage, and die after 3 days when fed a choline-deficient diet; choline supplementation 
prevents this [40]. Pemt-/- mice have lower choline pools in the liver despite being fed 
sufficient or supplemental choline, suggesting that choline production by PEMT in the liver 
is a significant source of choline relative to dietary choline [41]. AdoMet, the methyl donor 
required for PEMT action, is a product of BHMT (as discussed below). BHMT could 
potentially affect PtdCho synthesis via both CDP-Choline and PEMT pathways.  
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2.2.2 BHMT and Homocysteine and One-Carbon Metabolism 
 
Homocysteine is a thiol-containing amino acid that is potentially harmful. Humans 
who have plasma total homocysteine (tHcy) of 10 to 100 µmol/L are considered to be 
moderately hyperhomocysteinemic, while tHcy >100 µmol/L is considered to be severe 
hyperhomocysteinemic [42]. Elevation of tHcy is associated with cardiovascular disease, 
neural tube defects, renal insufficiency, Alzheimer’s, and cognitive impairment in the elderly 
[43]. Moderate hyperhomocysteinemia (HHcy) is common in humans. It is detected in 10-
20% of the general population as a result of genetic or non-genetic factors (such as diet, 
drugs, and impaired renal function) [43]. It is detected in up to 20-40% of patients with 
cardiovascular complications [42].   
 
Hcy is metabolized by both transsulfuration and transmethylation processes. In the 
transsulfuration pathway, Hcy forms cystathionine and then cysteine in reactions catalyzed 
by the enzymes cystathionine-β-synthase (CBS, EC 4.2.1.22) and cystathionine-γ-lyase (CγL, 
EC 4.4.1.1), respectively (Figure 2.4). Both enzymes require vitamin B6. Cystathionine-β-
synthase also requires AdoMet as the allosteric activator. Cysteine is the precursor to the 
osmolyte taurine and the antioxidant glutathione. In the transmethylation pathway, Hcy is 
remethylated to methionine by three reactions. BHMT and BHMT2 remethylate Hcy using 
betaine and S-methylmethionine as the methyl donor respectively. Methionine synthase (MS, 
EC 2.1.1.13) catalyzes the other reaction using methyl-tetrahydrofolate (MTHF) as the 
methyl donor. MTHF is supplied by methyl-tetrahydrofolate reductase (MTHFR, EC 
1.5.1.20) [44]. Methionine synthase also requires vitamin B12 as a cofactor. BHMT processes 
an estimated 50% of the Hcy methylated capacity in an in vitro model of rat liver [45].  
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Figure 2.4 Homocysteine metabolism. Enzymes that catalyze the reactions: (1) methionine 
adenosyltransferase (MAT); (2) different methyltransferases, particularly glycine N-
methyltransferase (GNMT); (3) SAH hydrolase (SAHH); (4) methionine synthase (MS); (5) 
betaine-homocysteine methyltransferase (BHMT); (5.2) betaine-homocysteine 
methyltransferase 2 (BHMT2); (6) cystathionine β-synthase (CBS); (7) cystathionase; (8) 
methylene-THF synthase (methyl-THF); (9) methyl-THF reductase (MTHFR); (10) 
thymidine synthase; (12) choline dehydrogenase (CHDH) and betaine aldehyde 
dehydrogenase (BADH) ; (13) thiolactone synthase; (14) adenosine kinase. Abbreviations: 
SAMe, S-adenosylmethionine; MTA, methylthioadenosine; SAH, S-adenosylhomocysteine; 
GSH, glutathionine; THF, tetrahydrofolate; methylene-THF, 5,10-methylene-tetrahydrofolate; 
methyl-THF, 5-methyl-tetrahydrofolate; dTMP, deoxythymidine monophosphate; DHF, 
dihydrofolate. Figure from Mato, J. Annu. Rev. Nutr. 2008; 28, 273-293. 
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Methionine, coming from either diet or the actions of MS and BHMTs, is the 
precursor of AdoMet. AdoMet is the principal biological methyl donor required for various 
cellular events, including the methylation of DNA, histones, phospholipids, biogenic amines, 
and other proteins. AdoMet is required for the synthesis of methylglycine from glycine by 
glycine N-methyltransferase (GNMT); for the formation of PtdCho from PtdEtn by PEMT; 
for the synthesis of cysteine and ultimately glutathione by the transsulfuration pathway; and 
many other methylation reactions (Figure 2.3 & 2.4). S-adenosylhomocysteine (AdoHcy) is 
formed after AdoMet donates its methyl group to diverse biological acceptors. AdoHcy then 
is hydrolyzed to form Hcy and adenosine by a reaction catalyzed by S-adenosylhomocysteine 
hydrolase (SAHH, EC 3.3.1.1) [46]. This reaction is reversible, but it favors the synthesis of 
AdoHcy, a potent inhibitor of many methylation reactions [46]. The ratio between AdoMet 
and AdoHcy (AdoMet:AdoHcy) estimates the methylation potential, as AdoMet is the 
universal methyl donor, while AdoHcy is an inhibitor for many known methyltransferases. 
 
Several pathways are evolutionarily conserved to maintain a normal level of Hcy and 
an adequate supply of AdoMet, suggesting the significance of these compounds. Animal 
models of HHcy have been produced either through dietary modifications (by limiting 
dietary choline, vitamin B6, vitamin B12, or methyl-folate) or through genetic approaches 
(Cbs-/-, Mthfr-/-, Ms-/- mouse models) [42]. Perturbations of these pathways have resulted in 
elevated plasma tHcy levels [47], in reduced methylation potential (AdoMet:AdoHcy) [48], 
and in compensatory changes of other Hcy pathways [49, 50]. During choline and betaine 
deprivation, more 5-methyltetrahydrofolate is used for Hcy remethylation. Conversely, 
during folate deficiency, methyl groups from choline and betaine are used for Hcy 
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remethylation, thereby increasing choline and betaine requirements. BHMT interrelates with 
the transsulfuration and methylfolate pathways at the removal of Hcy. The Bhmt-/- mouse 
model was not created until this work was done. The lack of attention to BHMT’s role in Hcy 
removal is probably due to the assumption that the alternative pathways could replace BHMT. 
 
2.3 Physiological Implications of Betaine and BHMT – Human Studies 
 
Reduced choline or methylation potential levels are associated with increased risk of 
cancer (as discussed below), while elevated Hcy levels are associated with increased risks of 
cardiovascular disease and neural tube defects. BHMT is the enzyme that integrates these 
pathways. Thus, epidemiological studies have focused on investigating the associations of 
human BHMT mutations with these diseases. Common single nucleotide polymorphisms 
(SNPs) in the BHMT gene in humans have been identified. These SNPs can alter BHMT 
protein level and enzyme activity [12]. The BHMT SNP rs3733890 (c.716G>A) is common; 
41% of the NC population have 1 variant allele, and 8% have 2 alleles [51]. This SNP has 
been associated with increased risk [52], decreased risk [53], and no change in risk [54] of 
having babies with neural tube defects. Humans with the BHMT SNP rs3733890 have 
reduced risk [55], or no change in risk [56, 57] of developing cardiovascular disease. The 
Long Island Breast Cancer Study Project (LIBSP) finds that patients with this SNP have no 
change in risk of breast cancer [58], but have reduced breast cancer-specific mortality [59]. 
The epidemiological evidence regarding the functional effects of BHMT SNPs remains 
controversial. 
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While some epidemiological studies focus on genetic interactions in the etiology of 
diseases, others focus on the nutrients in diets. Many studies examine the effect of dietary 
betaine in reducing plasma tHcy that could potentially contribute to vascular complications. 
Fifty percent of patients with classical genetic homocystinuria have an adverse vascular event 
before they reach 30 years of age [60]. A study with 15 patients who are supplemented with 
6-9 g betaine per day (average betaine intakes range from 100-30 mg/day) shows a 74% 
reduction in plasma tHcy levels and no vascular events over the course of a total of 258 
studied patient years [61]. Other studies using patients with inborn errors of Hcy metabolism, 
particularly errors in CBS and MTHFR, have reaffirmed this beneficial effect of betaine 
supplementation [62-65]. It is pertinent to note that betaine therapy could result in 
hypermethioninemia, causing cerebral edema in some patients [66, 67]. Aside from treating 
patients with genetic homocystinuria, betaine also reduces plasma tHcy in the general 
population with mild hyperhomocysteinemia. One study demonstrates that a dose of 6g 
betaine per day reduces plasma tHcy level by approximately 20% in normal adults [68]. 
Another study demonstrates that 95% of patients with premature peripheral or cerebral 
occlusive arterial disease respond to betaine (6g/day) with a normal level of tHcy [69]. While 
many studies have shown the effectiveness of betaine in reducing plasma tHcy levels [68, 70-
72], it remains a question whether betaine supplementation can serve as a preventative 
regimen for vascular dysfunction. Short or long-term betaine supplementation do not 
improve endothelial function in healthy subjects despite the reduced tHcy levels [72, 73]. A 
study on 3,000 healthy Greek men and women demonstrates that individuals with high intake 
of choline and betaine have low plasma levels of inflammatory markers, such as C reactive 
protein, interleukin-6, and tumor necrosis factor-α, suggesting a protective effect of choline 
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and betaine against cardiovascular disease [74]. However, two large prospective studies, 
Dutch PROSPECT-EPIC cohort and Atherosclerosis Risk in Communities (ARIC) study, 
find no association between the intake of choline and betaine and cardiovascular disease [75, 
76]. The protective role of betaine against vascular dysfunction requires future study. 
 
In addition to regulating Hcy levels, betaine appears to modify plasma lipid profiles, 
which further contributes to its potential role in altering cardiovascular risk. Recently, two 
independent cross-sectional studies reveal that increased plasma betaine is correlated with 
reduced plasma triacylglycerol and non-high density lipoprotein (non-HDL) cholesterol, 
which are the preferred plasma lipid profiles [77, 78]. In addition, in both studies, increased 
plasma betaine is associated with lower BMI in the study populations, suggesting a potential 
role of betaine in altering adiposity (as discussed below). In contrast, some studies argue that 
betaine supplementation increases plasma low density lipoprotein (LDL) cholesterol and 
triacylglycerol concentrations [70, 72, 79], effects that may counterbalance its Hcy lowering 
effects. However, the rise in LDL concentration may be an artifact of betaine increasing 
VLDL and triacylglycerol excretion from fatty liver to plasma, which is not an adverse 
outcome [80]. 
 
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and is 
associated with components of the metabolic syndrome [81]. Betaine treatment of NAFLD 
has been evaluated in three human studies. When treated with betaine, patients with 
nonalcoholic steatohepatitis have improved liver function, including reduced hepatic steatosis 
and attenuated hepatic or plasma aminotransferases [82-84]. Information on the relationship 
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of dietary betaine and cancer risk in humans is scarce, because food composition data have 
not been available until recently. The Long Island Breast Cancer Study Project finds that 
high choline consumption reduces breast cancer risk [58], and high choline and betaine 
consumption reduces breast cancer mortality [59]. However, two later reports find no 
association between betaine and choline intake and cancer, either breast cancer [85] or 
ovarian cancer [86]. There are no data on the effect of betaine supplementation on cancer risk. 
 
The evidence from human studies regarding the functional effects of BHMT 
mutations and dietary betaine intake in diseases remains controversial and warrants more 
studies. Nevertheless, these data suggest the importance of betaine/BHMT in the etiology and 
as a potential treatment of these diseases. 
 
2.4  Physiological Implications of Betaine and BHMT – Animal Studies 
 
Betaine is known for ameliorating the adverse effects of both nonalcoholic and 
alcoholic induced fatty liver. Fatty liver may progress to severe liver damage such as fibrosis 
and cirrhosis [87]. Alcoholic fatty liver is induced by excessive alcohol intake and is often 
associated with disturbed Hcy metabolism [88-90]. Betaine supplementation mitigates the 
adverse effects of alcoholic fatty liver, including reducing steatosis and maintaining Hcy and 
AdoMet levels [91-94]. Transgenic mice overexpressing human BHMT are resistant to 
alcohol-induced hepatic hyperhomocysteinemia and steatosis [95]. On the other hand, 
nonalcoholic fatty liver is commonly associated with obesity [96], insulin resistance, and 
diabetes [97]. Mice fed a high fat diet develop nonalcoholic fatty liver and insulin resistance, 
while betaine supplementation ameliorates these outcomes [98, 99]. 
 17 
 
 
The mechanisms by which betaine/BHMT improves hepatic steatosis are not 
thoroughly understood. Several mechanisms have been proposed. Betaine supplementation 
and its consequent BHMT induction generate AdoMet. AdoMet supplies the methyl groups 
needed for the synthesis of PtdCho from PtdEtn by PEMT. PtdCho enables the generation of 
VLDL, needed for secreting fat from the liver, thus ameliorating hepatic steatosis [100]. In 
addition, cultured hepatocytes overexpressing Bhmt, and rat livers following an in vivo 
induction of Bhmt, have increased apolipoprotein B expression [101-103]. These data suggest 
that betaine/BHMT might have multiple beneficial effects in lipoprotein synthesis. Others 
propose a role of betaine in reducing cellular stress [93, 104]. The antioxidant glutathione 
comes from cysteine, the generation of which requires AdoMet (Figure 2.4). Glutathione 
scavenges free radicals and is particularly important in mitochondria. The mitochondria are 
the primary intracellular site of oxygen consumption and the major source of reactive oxygen 
species (ROS) [105]. Glutathione maintains the redox balance and protects cells from 
oxidative stress [105]. One proposed mechanism is that betaine/BHMT restores AdoMet and 
glutathione concentrations, attenuates oxidative stress, and prevents further liver damage 
[104, 106, 107]. A growing body of evidence demonstrates that high Hcy induces ER stress 
[93, 95, 101, 108]. ER is an essential organelle, which provides a specialized environment for 
the production and post-translational modifications of secretory and membrane proteins. One 
proposed mechanism suggests that Hcy can be wrongly incorporated to proteins, causing 
protein misfolding and unfolding in the ER [93, 95, 101, 108]. An accumulation of these 
wrongly folded proteins then induces ER stress. ER stress activates Srebp1c (sterol 
regulatory element binding protein 1c), an ER bound transcription factor that induces lipid 
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synthesis. Activation of Srebp1c further contributes to the development of fatty liver [108]. 
Betaine/BHMT system may protect liver through reducing HHcy induced ER stress. 
Hepatocytes overexpressing Bhmt and transgenic mice expressing human BHMT were 
resistant to HHcy induced ER stress and cell death [95, 101]. 
 
In addition to reducing hepatic steatosis and preventing further liver damage, 
betaine/BHMT has a potential role in enhancing insulin sensitivity. Betaine supplementation 
alleviates insulin resistance and reduces hepatic steatosis in a high-fat-fed mouse model [99]. 
When supplemented with betaine, epidermal fat pad and adipocytes isolated from high-fat-
fed mice have increased activation (phosphorylation) of protein kinase B (PKB/Akt) and 
extracellular signal-regulated kinases (ERK) that are normally suppressed by high-fat-diet 
[99]. PKB/Akt and ERK are two principal downstream kinases in the insulin-signaling 
pathway. This finding suggests that betaine could ameliorate fatty liver by improving insulin 
function in adipose tissue. Another study demonstrates that betaine treatment reverses the 
inhibition of hepatic insulin signaling in high-fat-fed mice and insulin-resistant HepG2 cells 
[98]. Betaine supplementation increases the activation of insulin receptor substrate 1 (IRS1), 
leading to enhanced glycogen synthesis and reduced gluconeogenesis. Taken together, these 
studies suggest roles for betaine/BHMT in alleviating fatty liver, fatty liver related cellular 
injury and insulin resistance.   
 
An alternative way to study gene function is by studying the engineered knockout 
(deletion) mouse models. A Bhmt knockout mouse model was not available until now. 
Previously, a potent inhibitor of BHMT, S-(δ-carboxybutyl)-DL-homocysteine (CBHcy), was 
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administered intraperitoneally to mice [109] or fed to rats [110] to study the physiological 
implications of BHMT deficiency. Administration of CBHcy causes an elevation of plasma 
tHcy concentration and a reduction in hepatic AdoMet:AdoHcy ratio, reaffirming the role of 
BHMT in regulating Hcy and methyl donors. In these studies, inhibition of Bhmt does not 
affect markers of hepatic health such as fatty liver and plasma alanine transaminase. The lack 
of effects is probably due to a short term or an incomplete inhibition of BHMT. 
 
2.5 One-Carbon Metabolism and Cancer 
 
In 2008, the American Cancer Society (www.cancer.org) projected that about 780,300 
people worldwide would have new liver cancer cases, and about 695,500 people would die 
from liver cancer. In 2011, an estimated 26,190 new cases of liver cancer and 19,590 liver 
cancer deaths are expected in the United States alone. Hepatocellular carcinoma (HCC) 
accounts for >80% of liver cancer cases. Liver cancer is among the most lethal cancers (five-
year survival rates under 14%), making it the fifth most frequent cause of cancer death in 
American men and the ninth in American women [111]. The incidence rates are highest 
among Asian Americans/Pacific Islanders and Hispanics [111].  
 
Mouse models for HCC are used to understand the molecular mechanisms underlying 
the pathogenesis of HCC. These mouse models are often genetically modified or cancers are 
induced by agents such as diethylnitrosamine, aflatoxin, and phenobarbital. Choline is the 
only nutritional deficiency that causes liver cancer without any known carcinogen [112]. In 
rodents, choline deficiency results in a higher incidence of spontaneous HCC [112]. Cancer 
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initiates with DNA damage within cells. Cancer ensues when these cells fail to repair and to 
recognize the DNA damage, and fail to die by apoptosis. Several mechanisms have been 
suggested for choline deficiency’s carcinogenic effects. One proposed mechanism is based 
on the observation that rats fed a choline-deficient diet have increased lipid peroxidation in 
the liver [113]. Lipid peroxidation refers to the oxidative degradation of lipids, producing 
free radicals that can modify DNA in the nucleus and induce carcinogenesis. Another 
proposed mechanism is that choline deficiency perturbs signaling transduction. Large 
amounts of PtdCho are synthesized from choline and diacylglycerol (DAG) in cells. In cased 
of choline deficiency, PtdCho synthesis is diminished and DAG accumulates. DAG activates 
protein kinase C signaling cascades, resulting in altered cell proliferation signals and cell 
apoptosis and finally in carcinogenesis [114].  
 
Methyl deficiency may also mediate the mechanisms that underlie the etiology of 
cancers. As discussed previously, AdoMet is required for the synthesis of the antioxidant 
glutathione, which attenuates oxidative stress by scavenging free radicals, protecting cells 
from DNA damage. Methyl deficiency may also affect DNA via epigenetic modification, 
such as DNA and histone methylation. DNA methylation predominantly involves the 
covalent addition of a methyl group to the 5’ position of cytosine that precedes a guanosine 
(CpG) in the DNA sequence. This is referred to as an epigenetic modification since it does 
not change the coding sequence of the DNA. When DNA methylation occurs in the promoter 
regions, the expression of the associated gene is altered [115, 116]. Methylated CpG prevents 
the binding of the transcription factors, while unmethylated CpG allows the binding of the 
transcription factors to the gene [115, 116]. These actions alter gene expression based on the 
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roles of the transcription factors. For example, if the binding of the transcription factor is 
associated with inducing gene expression, then DNA methylation will result in gene 
silencing, and vice versa. Although there are exceptions, increased DNA methylation is 
usually associated with gene silencing, while decreased methylation usually associates with 
increased gene expression [117]. AdoMet is required for DNA methylation, while AdoHcy 
inhibits the methyltransferases. Methyl deficiency may alter epigenetic machinery by 
hypomethylating and paradoxically hypermethylating specific genes (e.g. tumor suppressor 
genes). Consequently, the expression of tumor suppressor genes responsible for DNA repair 
(BRCA1, hMLH1), cell cycle regulation (p15, p16), carcinogenesis metabolism (GSTP1), 
hormonal response (RARβ2), apoptosis (DAPK, APAF-1), cell adherence (CDH1, CDH3) 
[118-120] are silenced, leading to tumor development. Two mouse models with disturbed 
methyl group metabolism demonstrate the importance of methyl groups in cancer etiology. 
Methionine adenosyltranferase 1A knockout mouse model (cannot make AdoMet from 
methionine) has a persistent decrease in AdoMet concentration in the liver, leading to the 
development of HCC [121]. Glycine N-methyltransferase (GNMT) catabolizes AdoMet to 
AdoHcy, hence regulates the ratio of AdoMet/AdoHcy. The GNMT knockout mouse model 
has liver AdoHcy concentration 71 times higher than that of controls. These mice have 
steatosis and liver fibrosis after 3 months [122], and develope multifocal HCC at 8 months 
[123]. Together, these data demonstrate the importance of DNA methylation in cancer 
etiology. 
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2.6 Energy Metabolism and Insulin Sensitivity 
 
The pathogenesis of obesity is complex, involving multiple organs and endocrine 
systems. Liver, white adipose tissue and brown adipose tissue are the key regulators of 
energy homeostasis. During glucose abundance (feeding), both adipose and liver can utilize 
glucose to synthesize lipid in the form of triacylglycerol [124]. Glucose provides glycerol 
phosphate, the backbone for triacylglycerol synthesis [124]. Excess glucose also forms acetyl 
CoA for de novo fatty acid synthesis [124]. Liver does not usually store lipid. Therefore, the 
synthesized TAG is packaged into VLDL and transported from the liver to circulation, where 
FA are taken up and stored in adipose tissue [87]. Liver can also store glucose as glycogen. 
White adipose tissue serves as an energy reservoir [125, 126]. It stores fuel in the form of 
triacylglycerol during energy excess and breaks down triacylglycerol and releases glycerol 
and fatty acids during energy deprivation [125, 126]. Glycerol and fatty acids from lipolysis 
then serve as fuels for organs. Fatty acids can be catabolized by β oxidation in the 
mitochondria, a step in which carnitine is required. White adipose tissue also acts as an 
endocrine organ; it may regulate glucose balance by secreting glucose regulating factors such 
as leptin, adiponectin, and tumor necrosis factor-α (TNF-α) [125, 126]. Brown adipose tissue 
functions to regulate thermogenesis, providing heat to mammals during cold exposure to 
maintain body temperature. Different from white adipose tissue, brown adipose tissue 
contains multi-locular lipid droplets, a high abundance of mitochondria, and a large amount 
of uncoupling protein 1 (UCP1) [127]. UCP1 allows the hydrogen ions to pump through the 
electron transport chain and release as heat instead of ATP [127]. Finally, the brain can sense 
nutrient availability and respond by altering food intake and stimulating the release of factors 
that regulate energy metabolism [128]. Taken together, homeostasis of energy stores is 
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regulated by mechanisms including modulation of metabolic rate and thermogenesis, 
regulation of metabolite fluxes among various organs, and modulation of fuel synthesis and 
usage within adipose tissue. 
 
Alteration in fat stores in organs is associated with altered insulin sensitivity and 
glucose balance [126]. Insulin is a peptide hormone that is secreted by pancreatic β cells in 
response to elevated glucose levels after feeding [124, 129]. Insulin regulates blood glucose 
concentration via increasing glucose uptake by adipose tissue and muscle and inhibiting 
hepatic glucose production [124, 129]. Insulin also promotes the storage of glucose as 
glycogen in liver, and as triacylglycerol in adipose tissue. Insulin binds to the insulin receptor 
on cells. The receptor’s tyrosine kinase activity autophosphorylates and activates the receptor, 
leading to recruitment and activation of insulin receptor substrate proteins (IRS) [124, 129]. 
IRS proteins initiate signaling cascades that mediate a variety of cellular processes, including 
glycogen synthesis and gluconeogenesis. IRS activates PKB/Akt (protein kinase B) via 
phosphorylation. PKB/Akt then inactivates (phosphorylates) GSK3β (glycogen synthase 
kinase 3β), which functions to inhibit glycogen synthase activity [124, 129]. Therefore, 
insulin’s inhibition of GSK3β leads to enhanced glycogen synthesis [124, 129]. PKB/Akt 
also inactivates (phosphorylates) FoxO1 (Forkhead box protein O1), which normally induces 
Pepck (phosphoenolpyruvate carboxykinase), a gene involved in gluconeogenesis [124, 129]. 
Insulin reverses this induction, leading to suppressed gluconeogenesis [124, 129]. In adipose 
tissue, insulin enhances glucose uptake by stimulating glucose transporter 4 (GLUT4) and 
induces the expression of several lipogenic enzymes, leading to increased fatty acid and 
triacylglycerol synthesis [124, 129]. Insulin also inhibits lipolysis in adipocytes through the 
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inhibition of hormone sensitive lipase [124, 129]. Alterations in insulin receptor 
concentrations, IRS proteins concentrations, the translocation of glucose transporters, and the 
activities of various kinases and intracellular enzymes all contribute to insulin sensitivity and 
adiposity.  
 
Several hormones and growth factors have been identified as important regulators of 
energy homeostasis and glucose metabolism. In this dissertation, we observed changes in the 
thyroid hormone, bile acids and fibroblast growth factor 21 (FGF21), all of which are 
associated with increased energy expenditure. The thyroid hormone has long been accepted 
to have a major impact on the basal metabolic rate [130]. The thyroid gland secretes two 
forms of thyroid hormone - the predominant but inactive form, thyroxine (T4), and the active 
form, triiodothyronine (T3). Thyroid hormone binds to its receptors. There are two forms of 
thyroid hormone receptor (TR) – TRα1 is typically found in adipose tissue, muscle, brain and 
heart tissues, while TRß is in liver and kidney tissues [131]. Within the cell, the inactive 
prohormone T4 is converted to T3 by the enzyme deiodinase II, which is induced by bile acid 
[132, 133]. In adipose tissue, thyroid hormone functions to stimulate thermogenesis, lipolysis 
and lipogenesis simultaneously [134]. With these processes, thyroid hormone results in 
increased oxygen consumption and metabolic rate. Thyroid hormone also regulates glucose 
metabolism via enhancing glucose transporter GLUT4 expression [135]. In the liver, thyroid 
hormone induces HMG-CoA reductase, the rate-limiting enzyme for de novo cholesterol 
synthesis [130]. This results in an enhanced synthesis of cholesterol in hyperthyroidism. 
However, there is an inverse relationship between thyroid hormone and serum cholesterol 
[136] because thyroid hormone may simultaneously affect the synthesis and degradation of 
 25 
 
LDL cholesterol [137]. Thyroid hormone also induces cholesterol 7α hydroxylase (CYP7A1), 
the rate-limiting enzyme in bile-acid synthesis from cholesterol [138, 139]. This results in an 
enhanced synthesis of bile acids from cholesterol in hyperthyroidism. Taken together, thyroid 
hormone induces cholesterol turnover and bile acids synthesis.  
 
A novel concept indicating a signaling role of bile acids (BAs) in the control of 
energy metabolism has emerged [132, 133]. CYP7A1 catalyzes the conversion of cholesterol 
to 7α hydroxycholesterol, which is subsequently converted to bile acids. Cholic acid and 
chenodeoxycholic acid are the primary bile acids and often conjugate with taurine (as 
taurocholate or taurochenodeoxycholate) or glycine (as glycocholate or 
glycochenodeoxycholate) forming bile salts. Mice fed a cholic acid supplemented diet have 
increased energy expenditure, and are protected from diet-induced obesity and insulin 
resistance [133]. On the contrary, mice that have reduced bile acids have decreased energy 
expenditure and increased body fat [132]. Although debatable, it is suggested that bile acids 
increase energy expenditure via inducing deiodinase 2, the enzyme that converts T4 to T3 
within cells. It is interesting to note the interactions between thyroid hormone and bile acids. 
Thyroid hormone induces the synthesis of bile acids from cholesterol in the liver [138, 139]. 
In return, bile acids induce energy metabolism, perhaps through the activation of thyroid 
hormone [132, 133].  
 
Fibroblast growth factor 21 (FGF21) is a member of the FGF superfamily that is 
synthesized predominantly in the liver and released into circulation [140]. FGF21 plays a 
critical role in energy metabolism. In mice, hepatic Fgf21 expression is induced by fasting 
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and is regulated by Pparα (peroxisome proliferator activated receptor α), Pparγ, and 
ChREBP (carbohydrate response element binding protein) [141-143]. FGF21 increases 
glucose uptake [142, 144] and decreases intracellular TAG content in adipocytes [144]; it 
lowers plasma glucose and TAG when administered to diabetic mice [142]; and it increases 
energy expenditure and improves insulin sensitivity in diet-induced obese mice [145, 146]. 
Like bile acids, FGF21 appears to interact with thyroid hormone. Thyroid hormone treatment 
induces hepatic Fgf21 expression in a Pparα dependent manner [147]. FGF21 also appears to 
interact with bile acids. The evidence comes from recent studies carried out in patients with 
nonalcoholic steatohepatitis (NASH). These studies demonstrate that plasma bile acids and 
FGF21 concentrations are elevated in patients with NASH [148, 149]. The authors suggest 
that bile acids induce hepatic Pparα, which activates Fgf21, resulting in increased hepatic 
fatty acid oxidation in NASH patients [148, 149]. FGF21, bile acids and thyroid hormone all 
induce similar metabolic changes such as energy expenditure and glucose uptake. All of 
these molecules are altered in the Bhmt-/- mice. The interactions between these molecules and 
Bhmt deficiency remain to be elucidated. 
 
2.7 One-Carbon Metabolism, Energy Metabolism, and Adiposity  
 
There has been no direct evidence that BHMT is involved in energy metabolism. 
However, there is accumulating data that BHMT’s substrate betaine and betaine’s precursor 
choline may be involved in energy metabolism. Diets deficient in choline alone, or both 
choline and methionine, have been used to investigate aspects of metabolic syndrome, 
particularly non-alcoholic fatty liver and insulin resistance. Mice fed a methionine and 
choline deficient (MCDD) diet develop hepatic steatosis due to impaired PtdCho 
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biosynthesis. Compared to controls, MCDD-fed mice have a 37% increase in metabolic rate, 
leading to a 26% loss of body weight [150]. Peripheral insulin action has been reported to be 
normal [151] or improved [152, 153] in MCDD-fed rodents. Mice fed a high fat diet without 
choline (but with methionine) have better insulin sensitivity and improved glucose tolerance 
compared to high-fat-choline-fed mice [154]. Mice with the Pemt (making PtdCho from 
PtdEtn) gene deleted have normal metabolic parameters on a regular chow diet compared to 
wildtype controls [155]. However, when fed a high fat diet, they have increased energy 
expenditure, accumulate less body fat, and have increased glucose sensitivity [155]. The lack 
of weight gain in Pemt-/- mice disappears when mice are fed a diet supplemented with choline. 
These observations suggest a potential role of choline deficiency in modulating energy 
metabolism and insulin sensitivity.  
 
Betaine is widely discussed as a “carcass modifier” due to its lipotropic and growth-
promoting effects, generating leaner meat [156]. Betaine was originally introduced to the 
feed industry as a substitute for methionine and choline in diets for livestock. This was done 
based on economic interest and the possibility that betaine may enhance methionine and 
choline availability. Numerous investigations have been carried out to evaluate the 
effectiveness of dietary betaine supplementation on livestock (Table 2.2) [156-181]. In 
poultry, betaine supplementation resultes in reduced abdominal fat [156-181]. In pigs, 
betaine supplementation reduces carcass fat by 10-18% and increases lean mass by 4-8% 
[156-181]. The reduction of total carcass fat content is reflected by reduction in backfat 
thickness in pigs [156-181].  
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Information on the mechanisms of how betaine reduces the fat content of animals is 
scarce, though some mechanisms have been proposed. Betaine supplementation may increase 
the availability of methionine, perhaps explaining the increased protein production [156]. 
Betaine may enhance the synthesis of carnitine (a methylated compound formed from 
methionine and lysine), which is required for transporting long-chain fatty acids into 
mitochondria, where fatty acid oxidation takes place. Carnitine in liver and muscle increases 
from 9% to 53% in betaine supplemented poultry and pigs [156, 175]. However, there is no 
evidence that increased carnitine concentration translates into increased fatty acid oxidation. 
One study shows that betaine has no significant impact on β-oxidation in either in vivo or in 
vitro system in pigs [182]. Other studies suggest that betaine supplementation reduces body 
fat via reducing lipid synthesis and/or enhancing lipid breakdown. Betaine supplementation 
decreases the activities and the gene expressions of fatty acid synthesis, acetyl-CoA 
carboxylase, and malic enzyme (enzymes involved in lipogenesis) in the subcutaneous 
adipose tissue in pigs [183, 184]. In addition, betaine supplementation increases hormone 
sensitive lipase activity (enzyme involved in lipolysis) in broilers [185] and pigs [183].  In 
the agouti mouse model, the transgenerational amplification of obesity is prevented when 
mice are fed a diet high in betaine and choline, suggesting that epigenetic methylation is 
involved [186]. Most studies show interactions of betaine with growth-regulating and 
metabolic factors (Table 2.3) [172, 175, 179, 181, 187-191]. Betaine supplementation 
elevates the plasma growth hormone (GH) level between 46 to 102%, and the insulin-like 
growth factor 1 (IGF-1) level between 39 to 75 % in pigs and poultry [156]. The dietary 
supplementation of betaine also increases serum levels of triiodothyronine (T3) and 
thyroxine (T4) in pigs and poultry [156]. The direct interactions of betaine with these 
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hormones are not fully understood. However, there is evidence that betaine is linked to 
thyroid hormone (T3 and T4) secretion, since thyroidectomy induces an increase in the 
activity of BHMT [192].  
 
Betaine supplementation has been advertised to humans due to its potential role in 
reducing obesity. However, its lipotropic property has not been demonstrated in humans. A 
12-week study of betaine supplementation finds no effect on body fat and resting energy 
expenditure in obese adult subjects [70]. Alternatively, in a population-based study, plasma 
betaine is inversely related to the components of metabolic syndrome (BMI, % body fat, 
waist circumference, glucose, non-HDL cholesterol) and positively related to HDL 
cholesterol [77, 193]. These data suggest that BHMT and its metabolites, such as choline and 
betaine, may have a role in the regulation of energy metabolism and adiposity.  
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Table 2.2 Effect of betaine on carcass composition in pigs and poultry 
Table from Eklund M. Nutrition Research Reviews 2005; 18, 31-48. 
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Table 2.3 Effect of betaine on hormone levels in pigs and poultry 
Table from Eklund M. Nutrition Research Reviews 2005; 18, 31-48  
  
 
 
 
 
CHAPTER III 
THE ROLE OF BHMT IN ONE-CARBON METABOLISM AND LIVER HEALTH 
 
DELETION OF BETAINE-HOMOCYSTEINE S-METHYLTRANSFERASE IN MICE 
PERTURBS CHOLINE AND 1-CARBON METABOLISM, RESULTING IN FATTY 
LIVER AND HEPATOCELLULAR CARCINOMA1 
 
Ya-Wen Teng, Mihai G. Mehedint, Timothy A. Garrow, and Steven H. Zeisel 
 
 
3.1 ABSTRACT 
 
Betaine-homocysteine S-methyltransferase (BHMT) uses betaine to catalyze the conversion 
of homocysteine (Hcy) to methionine. There are common genetic polymorphisms in the 
BHMT gene in humans that can alter its enzymatic activity. We generated the first Bhmt-/- 
mouse to model the functional effects of mutations that result in reduced BHMT activity.  
 
______________________________ 
1Teng, Y., Mehedint, M.G., Garrow, T.A., and Zeisel, S.H. (2011). Deletion of Murine 
Betaine-Homocysteine S-Methyltransferase in Mice Perturbs Choline and 1-Carbon 
Metabolism, Resulting in Fatty Liver and Hepatocellular Carcinoma. JBC. 286(42):36258-67. 
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Deletion of Bhmt resulted in a 6-fold increase (p<0.01) in hepatic and an 8-fold increase 
(p<0.01) in plasma total Hcy concentrations. Deletion of Bhmt resulted in a 43% reduction in 
hepatic S-adenosylmethionine (AdoMet) (p<0.01) and a 3-fold increase in hepatic S-
adenosylhomocysteine (AdoHcy) (p<0.01) concentrations, resulting in a 75% reduction in 
methylation potential (AdoMet:AdoHcy) (p<0.01). Bhmt-/- mice accumulated betaine in most 
tissues, including a 21-fold increase in the liver concentration compared to wildtype (WT) 
(p<0.01). These mice had lower concentrations of choline, phosphocholine, 
glycerophosphocholine, phosphatidylcholine and sphingomyelin in several tissues. At 5 
weeks of age, Bhmt-/- mice had 36% lower total hepatic phospholipid concentrations and a 6-
fold increase in hepatic triacyglycerol concentrations compared to WT (p<0.01), which was 
due to a decrease in the secretion of very low density lipoproteins. At 1 year of age, 64% of 
Bhmt-/- mice had visible hepatic tumors. Histopathological analysis revealed that Bhmt-/- mice 
developed hepatocellular carcinoma (HCC) or carcinoma precursors. These results indicate 
that BHMT has an important role in Hcy, choline and one-carbon homeostasis. A lack of 
Bhmt also affects susceptibility to fatty liver and HCC. We suggest that functional 
polymorphisms in BHMT that significantly reduce activity may have similar effects in 
humans. 
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3.2 INTRODUCTION  
 
Betaine-homocysteine S-methyltransferase (BHMT) is a zinc dependent cytosolic 
enzyme that catalyzes the transfer of a methyl group from betaine to homocysteine (Hcy) 
forming dimethylglycine (DMG) and methionine (Met). Humans have common single 
nucleotide polymorphisms (SNPs) in the BHMT gene that alter BHMT enzyme activity and 
function [12]. A common BHMT SNP rs3733890 (41% of NC population has 1 variant allele, 
and 8% have 2 alleles [51]) was associated with increased risk for having babies with neural 
tube defects (NTDs) [53], decreased risk for developing cardiovascular disease [55] and 
reduced risk for breast cancer-specific mortality [59]. The epidemiological evidence suggests 
the importance of SNPs in the gene. However, the metabolic consequences of having null 
mutations of BHMT gene have not been thoroughly-investigated. To directly investigate the 
role of BHMT in vivo, we generated and characterized mice in which the gene encoding 
Bhmt was deleted (Bhmt-/-). 
 
BHMT activity is found at high levels in the liver and kidney, and low levels in the 
brain, lenses and other human tissues. In rodents, high levels of BHMT activity are only 
found in the liver [18]. Betaine, the methyl donor for BHMT, comes from either dietary 
sources or from oxidation of choline (an irreversible reaction) by choline dehydrogenase 
(CHDH). Alternatively, choline can be used to form the phospholipid phosphatidylcholine 
(PtdCho) or the neurotransmitter acetylcholine [194]. The product of BHMT, methionine, is 
the precursor for S-adenosylmethionine (AdoMet), the major methyl donor for most 
biological methylations, including DNA and histone methylation, the conversion of glycine 
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to methylglycine (catalyzed by glycine methyltransferase (GNMT)), and the methylation of 
phosphatidylethanolamine (PtdEtn) to form PtdCho (catalyzed by phosphatidylethanolamine-
N-methyltransferase (PEMT)). 
 
The other substrate for BHMT is Hcy, a thiol-containing amino acid, which, when 
elevated in plasma, is associated with cardiovascular diseases, pregnancy complications, 
renal insufficiency and cognitive impairment [43]. Hcy is converted to methionine by BHMT 
or by methionine synthase (MS), the latter of which uses methyltetrahydrofolate (methylTHF) 
as the methyl donor (supplied by methylenetetrahydrofolate reductase (MTHFR)) [195]. 
Alternatively, Hcy is removed by the trans-sulfuration pathway, forming cystathionine and 
cysteine catalyzed by the enzymes cystathionine-β-synthase (CBS) and cystathionine-γ-lyase 
(CγL), respectively [195]. Both enzymes require vitamin B6; CBS also requires AdoMet as 
the allosteric activator [195].  All the above pathways might be perturbed with the deletion of 
Bhmt. Here, we report on the metabolic phenotype of the first Bhmt knockout mouse created.  
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3.3 EXPERIMENTAL PROCEDURES 
 
Generation of Bhmt-/- mice - The gene targeting vector was designed to remove exons 6 and 
7, the zinc binding domains of the gene (Figure 3.1A). The targeting vector was constructed 
by placing a MC1-neomycin (Neo) selectable marker flanked by 2 flippase (FLP) recognition 
target (FRT) sites and 1 locus of X-over P1 (loxP) site ~330 bp downstream of exon 7. A 
second loxP site was introduced ~240 bp upstream of exon 6. The vector was electroporated 
into E14Tg2A embryonic stem (ES) cells. Targeted cells were screened by PCR, confirmed 
by Southern-blot analysis, and injected into blastocysts derived from mouse strain C57Bl/6 to 
create Bhmt transmitting chimeras. Neo deleted mice were generated by crossing the 
transmitting chimeras with Flpe deleters (#003800, Jackson Laboratory, Bar Harbor, ME), 
which expressed Flpe recombinase that recognized FRT sites and deleted the Neo cassette. 
Bhmt knockout (KO) mice were generated by crossing the Neo deleted mice with Cre 
deleters (#003724, Jackson Laboratory), which expressed Cre recombinase that recognized 
loxP sites and deleted exons 6 and 7. Bhmt KO mice were continuously backcrossed to 
C57Bl/6 mice. Generations F1 to F4 were used in this study.  
For all experiments, Bhmt+/+, Bhmt+/-, and Bhmt-/- littermates born of Bhmt+/- mating 
pairs were used to control the mixed genetic background. Mice were genotyped by PCR 
using TaKaRa Ex Taq DNA polymerase (TaKaRa Bio USA, Madison, WI) and the following 
primer sequences: Bhmt+/+  forward 5’-GACTTTTAAAGAGTGGTGGTACATACCTTG-3’, 
Bhmt+/+ reverse 5’-TCTCTCTGCAGCCACATCTGAACTTGTCTG-3’, Bhmt-/- forward 
5’TTAACTCAACATCACAACAACAGATTTCAG-3’, Bhmt-/- reverse 5’-
TTGTCGACGGATCCATAACTTCGTATAAT-3’. PCR conditions were as follows: 94°C 
 37 
 
for 2 min; 40 cycles of 94°C for 30 sec, 64°C for 2 min, and 72°C for 2 min; and 72°C for 6 
min. Bhmt+/+ PCR product was 1.6 kb in size, while Bhmt-/- was 545 bp (Figure 3.1B). The 
animals were kept in a temperature-controlled environment at 24°C and exposed to a 12h 
light and dark cycle. All animals received AIN-76A pelleted diet with 1.1 g/kg choline 
chloride (Dyets, Bethlehem, PA). The Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill approved all experimental protocols.   
 
Reproducibility, viability, body weight, body length, and life span - Pairs of Bhmt+/+, 
Bhmt+/-, and Bhmt-/- parents were bred to assess their reproductive potential. Sizes, genotype 
distribution, and gender distribution of litters were recorded. Body weights and lengths (nose 
to hip, nose to tail) of Bhmt+/+, Bhmt+/-, and Bhmt-/- mice were measured from age 3.5 to 20 
weeks old using a scale and a ruler respectively. Eleven Bhmt+/+, and fourteen Bhmt-/- mice 
were maintained over the course of a year to determine one-year survival rates.  
 
Western blot and enzymatic assay - Mice were anesthetized by inhalation of isoflurane 
(Hospira, Lake Forest, IL). Tissues were harvested, weighted, snap frozen, pulverized under 
liquid nitrogen and stored at -80oC until used. Western blot analysis of BHMT was 
performed in liver homogenate as previously described [196]. For all enzymatic assays, 
pulverized liver from 5-week-old mice were homogenized in buffer using a motorized tissue 
homogenizer (Talboys Engineering Corporation, Montrose, PA). BHMT activity was 
measured as the conversion of [14C]betaine to [14C]methionine and [14C]dimethylglycine as 
previously described [14]. CHDH activity was measured as the conversion of [14C]choline to 
[14C]betaine as previously described [197] using high pressure liquid chromatography (HPLC) 
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on a Varian ProStar HPLC system (PS-210, Varian Inc., Palo Alto, CA) with a Pecosphere 
Silica column, 4.6mm x 83 mm (Perkin Elmer, Norwalk, CA) and a Berthold LB506 C-1 
radiodetector (Oak Ridge, TN). GNMT activity was measured as the conversion of 
[3H]AdoMet to [3H]methylglycine using the charcoal absorption method as previously 
described [198]. PEMT activity was measured as the conversion of [3H]AdoMet to 
[3H]PtdCho as previously described [199, 200]. Protein concentrations were measured using 
the Bradford Assay [201]. 
 
Choline and homocysteine metabolites - Tissues from 5-week-old animals were harvested 
as described above. Blood was collected via cardiac puncture, and plasma isolated by 
centrifugation at 3000 rpm for 5 min at room temperature. The concentrations of choline 
metabolites were measured by liquid chromatography-electrospray ionization-isotope 
dilution mass spectrometry (LC–ESI–IDMS) as previously described [202]. The 
concentration of AdoMet and S-adenosylhomocysteine (AdoHcy) were measured using the 
Varian ProStar HPLC system as previously described [203, 204] with an Ultrasphere ODS 
5µm C18 column, 4.6mm x 25cm (#235329, Fullerton, CA) and a UV/VIS detector (model 
118, Gilson, Middleton, WI). Plasma total Hcy (tHcy) and cysteine were measured after 
derivatizing 50 µL of plasma with 7-fluorobenzofurazan-4-sulfonic acid. The derivatized 
products  were measured as previously described [205] using the Varian ProStar HPLC 
system with a Microsorb-MV 5µm C18 column, 4.6mm x 25cm (Varian) and a Prostar model 
360 fluorescence detector (Varian). Mercaptopropinylglycine (10 µM) was used as an 
internal standard. Hepatic tHcy, cystathionine, methionine, cysteine, methylglycine, 
dimethylglycine, and glycine were measured as previously described [206] using capillary 
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stable isotope dilution gas chromatography/mass spectrometry (Hewlett-Packard Co., Pal 
Alto, CA). Plasma total folate was measured using Lactobacillus casei assay as previously 
described [207]. 
 
Clinical analysis - Concentrations of plasma urea nitrogen (BUN) and creatinine as well as 
activities of lactate dehydrogenase (LDH), alanine transaminase (ALT), and creatinine kinase 
(CK) were measured using an automatic chemical analyzer (Johnson and Johnson VT250, 
Rochester, NY) at the Animal Clinical Chemistry and Gene Expression Facility, UNC-
Chapel Hill. Urine specific gravity was measured using a refractometer (AO Instrument 
Company, Buffalo, NY) at the Department of Laboratory Animal Medicine Veterinary and 
Technical Services Facility, UNC- Chapel Hill. Plasma triacylglycerol (TAG), β-
hydroxybutyrate (Stanbio, Boerme, TX), cholesterol, high density lipoprotein cholesterol 
(HDL-C), non-esterified fatty acids (NEFA), and glucose (Wako, Richmond, VA) were 
measured colorimetrically per manufacturers’ instructions. 
 
Triacylglycerol, phospholipids, and cholesterol - PtdCho, PtdEtn, phosphatidylserine 
(PtdSer) and phosphatidylinositol (PtdIns) were extracted from 5-week-old mouse liver using 
the Bligh and Dyer method [208], and isolated by thin layer chromatography (TLC) [209]. 
Concentrations were determined using a phosphate assay [210]. TAG was extracted from 
liver samples using the Folch method [211] and measured colorimetrically as described 
above. 
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In vivo VLDL secretion rate - 5-week-old animals were fasted for 4 hours. 500 mg/kg BW 
of Triton WR1339 (as a 7.5% solution dissolved in in PBS) was injected retro-orbitally. 
Blood samples were taken using heparinized capillary tubes retro-orbitally at 2, 30, 60, and 
120 min after Triton WR1339 injection for TAG measurement as an indicator of the 
secretion rate of the very low density lipoprotein (VLDL).  
 
Tissue histology - Liver was harvested and fixed in 4% paraformaldehyde/0.2% 
gluteraldehyde for 48 hours. Liver was processed, paraffin embedded, sectioned at 5 µm, and 
stained with hemotoxylin and eosin as previously described [212]. For tumor analysis, whole 
liver was sectioned serially, and multiple sections per sample were examined by 2 veterinary 
pathologists from the Department of Laboratory Animal Medicine, UNC-Chapel Hill. High 
resolution images were collected using a Zeiss Axiovision A1 upright microscope. 
 
Gamma Glutamyltransferase 1 (gGT1) - gGT1 levels were determined using ELISA 
(Cedarlane, Burlington, NC). Frozen liver samples from 1-yr-old mice were homogenized in 
ice cold PBS at pH 7.0 containing 10% protease inhibitors (Sigma) using an ultrasonic cell 
disruptor. The resulting suspension was centrifuged and protein levels were determined by 
the Lowry method [213]. Equal amounts of proteins were loaded onto the ELISA plate 
according to manufacturer’s protocol. The optical density was read at 450nm on a Synergy 2 
microplate reader (Biotek, Vermont). 
 
Statistics - Statistical differences were determined using ANOVA, Tukey-Kramer HSD, and 
Student’s t-test JMP version 6.0; SAS Institute, Cary, NC) and reported as means ± SEM.  
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3.4 RESULTS 
 
Generation and validation of Bhmt knockout mice - Bhmt-/- mice were generated using a 
cre/loxP system to delete exons 6 and 7, which contain the zinc binding domain essential for 
BHMT activity. The mouse genotype was confirmed by PCR using genomic DNA (Figure 
3.1B). Bhmt-/- mice also were validated by assaying hepatic BHMT activity (Figure 3.1C) 
and by Western blot (Figure 3.1D). Deletion of 1 allele of Bhmt resulted in a 46% reduction 
of activity, while deletion of both alleles resulted in the absence of activity. BHMT protein is 
predominantly found in mouse liver and was absent in Bhmt-/- liver. 
 
Bhmt deletion had no effect on reproductive capacity or fetal viability - Mating pairs of 
Bhmt+/+, Bhmt+/-, and Bhmt-/- mice produced offspring with similar litter size (7.5 pups/litter) 
with evenly distributed genders. Bhmt+/- breeding pairs were used to generate littermates of 
Bhmt+/+, Bhmt+/-, and Bhmt-/- mice for all experiments. Bhmt+/- breeding pairs produced 
offspring at the expected Mendelian ratio, with 24.5% Bhmt+/+, 49.7% Bhmt+/-, and 25.8% 
Bhmt-/- mice. The Bhmt+/+ and Bhmt-/- mice appeared healthy and lived for at least 1 year. 
  
Bhmt-/- mice had reduced body weight at early age - Body length and weight of pups were 
monitored from 3.5 to 20 weeks of age. There was no significant difference in body length 
among Bhmt+/+, Bhmt+/-, and Bhmt-/- mice (data not shown), and in body weight between 
Bhmt+/+ and Bhmt+/- mice (Figure 3.1E). Bhmt-/- mice started with similar body weights as 
did Bhmt+/+ mice at weaning (3.5 wk), but gained less weight between 5 to 9 weeks of age 
(p<0.05). The weight difference did not persist after 9 weeks of age.  
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Bhmt deletion resulted in altered concentrations of choline and its metabolites - Bhmt is 
predominantly found in the liver, however, complete deletion of Bhmt (Bhmt-/-) resulted in a 
substantial increase in concentrations of betaine in liver (by 21-fold; p<0.001), kidney (by 5-
fold; p<0.001), heart (by 14-fold; p<0.001), brain (by 5-fold; p<0.001), muscle (by 12-fold; 
p<0.001), adipose (by 2-fold; p<0.001), lung (by 11-fold; p<0.001), and plasma (by 16-fold; 
p<0.001) compared to Bhmt+/+ mice (Table 3.1). Deletion of Bhmt resulted in reduced 
concentrations of choline in liver (by 82%; p<0.01), kidney (by 38%; p<0.01), heart (by 42%; 
p<0.05), and adipose (by 53%; p<0.01) compared to Bhmt+/+ mice. Deletion of Bhmt resulted 
in reduced concentrations of PtdCho in liver (by 26%; p<0.01), kidney (by 21%; p<0.05), 
heart (by 25%; p<0.01), muscle (by 25%; p<0.05), and plasma (by 31%; p<0.001) compared 
to Bhmt+/+ mice. Deletion of Bhmt resulted in reduced concentrations of phosphocholine 
(PCho) in liver (by 72%; p<0.01), heart (by 24%; p<0.05), muscle (by 65%; p<0.001), and 
adipose (by 68%; p<0.01) compared to Bhmt+/+ mice. Deletion of Bhmt resulted in reduced 
concentrations of glycerophosphocholine (GPCho) in liver (p<0.01), kidney (p<0.05), heart 
(p<0.001), adipose (p<0.05) and lung (p<0.01), as well as reduced concentrations of 
sphingomyelin (SM) in kidney (p<0.05) and heart (p<0.001) compared to Bhmt+/+ mice. In 
testis, there was no change in any choline metabolites in Bhmt-/- mice. Deletion of 1 copy of 
Bhmt (Bhmt+/-) resulted in choline metabolite concentrations in tissues similar to those of 
Bhmt+/+ mice (Table 3.6). 
 
Bhmt deletion resulted in altered concentrations of Hcy, AdoMet, AdoHcy and related 
metabolites - In liver, complete deletion of Bhmt resulted in a 43% decrease in AdoMet 
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concentrations (p<0.01), and a 2.6-fold increase in AdoHcy concentrations (p<0.01), 
resulting in a 76% reduction in methylation potential (AdoMet:AdoHcy) ratios (0.9 ± 0.1 in 
Bhmt-/- vs 3.6 ± 0.2 in Bhmt+/+; p<0.01) (Table 3.2). Bhmt-/- mice also had reduced hepatic 
concentrations of DMG (by 95%; p<0.001), but had increased hepatic concentrations of tHcy 
(by 6-fold; p<0.01) and methylglycine (by 2.6-fold; p<0.05) compared to Bhmt+/+ mice. 
Hepatic cystathionine, cysteine, methionine, and glycine did not differ among genotypes. In 
plasma, deletion of Bhmt resulted in increased concentrations of tHcy (by 7.8-fold; p<0.001), 
decreased concentrations of cysteine (by 48%; p<0.01), and decreased concentrations of total 
folate (by 35%; p<0.01) compared to plasma from Bhmt+/+ mice. Deletion of 1 copy of Bhmt 
(Bhmt+/-) did not result in changes in hepatic methylation potential, plasma tHcy, or plasma 
total folate compared to Bhmt+/+ mice (Table 3.7). Bhmt+/- had plasma cysteine 
concentrations between those of Bhmt+/+ and Bhmt-/- mice.       
 
Bhmt deletion resulted in altered activities of enzymes involved in one-carbon 
metabolism - Since Bhmt-/- mice (but not Bhmt+/- mice) had altered one-carbon metabolites, 
enzymes involved in one-carbon metabolism were measured in Bhmt+/+ and Bhmt-/- mouse 
liver. Complete deletion of Bhmt resulted in increased hepatic CHDH (by 1.33 fold; p<0.05) 
and GNMT (by 1.13 fold; p<0.05) activities (Figure 3.2). Hepatic PEMT activity was not 
affected by Bhmt deletion.   
 
Bhmt deletion resulted in increased hepatic fat accumulation and decreased 
phospholipids - At 5 weeks of age, hepatic TAG concentrations were 6.5-fold higher in 
Bhmt-/- mice than in Bhmt+/+ mice (p<0.05) (Figure 3.3C). Bhmt+/- mice had similar hepatic 
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TAG concentrations compared to that of Bhmt+/+ mice (8.96 ± 1.92 ug/mg tissue in Bhmt+/- 
vs 11.75 ± 0.99 ug/mg tissue in Bhmt+/+). The difference in hepatic steatosis between 
Bhmt+/+ and Bhmt-/- mice was easily visible at the microscopic level (Figure 3.3B). Hepatic 
and plasma phospholipids were measured in Bhmt+/+ and Bhmt-/- mouse liver due to their 
involvement with hepatic lipid storage and release. Bhmt-/- mice had lower concentrations of 
phospholipids in liver than did Bhmt+/+ mice (Figure 3.3A); with a 40% reduction in PtdCho 
(p<0.01), and a 60% reduction in PtdIns (p<0.01). Bhmt-/- mice also had a 31% reduction in 
plasma concentrations of PtdCho compared to Bhmt+/+ mice (p<0.01) (Table 3.1). PtdEth 
concentrations in liver and plasma were the same for both genotypes. Bhmt-/- mice had 
significantly reduced VLDL secretion rate (Figure 3.3D).  
 
Bhmt deletion resulted in altered clinical analyses - Plasma alanine aminotransferase 
activity, a measure of liver damage, was modestly increased in Bhmt-/- mice (34.7 ± 4.4 U/l in 
Bhmt-/- vs 20.6 ± 4.9 U/l in Bhmt+/+; p<0.05) (Table 3.3). Plasma BUN, creatinine, CK, and 
LDH, tests of kidney and muscle function, showed no changes in the Bhmt-/- mice. Urine 
specific gravity was significantly reduced in Bhmt-/- mice (1.020 ± 0.002 mg/dL in Bhmt-/- vs 
1.039 ± 0.005 mg/dL in Bhmt+/+; p<0.01). Plasma TAG, glucose, NEFA, and β-
hydroxybutyrate concentrations did not differ between genotypes. Compared to wildtype 
littermates, Bhmt-/- mice had significantly lower plasma total cholesterol concentrations (by 
45%, p<0.01) and HDL-C (by 38%, p<0.01). Heterozygous mice had similar plasma ALT, 
BUN, creatinine, LDH, CK, TAG, glucose, NEFA, and β-hydroxybutyrate concentrations 
compared to wildtype mice (Table 3.7). Heterozygous mice had no change in plasma 
cholesterol and HDL-C concentrations compared to Bhmt+/+ mice.      
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Bhmt deletion resulted in preneoplastic, neoplastic, and regenerative lesions in the 
mouse liver - Eleven Bhmt+/+, and fourteen Bhmt-/- mice were maintained over the course of 
a year to determine one-year survival rates. At time of sacrifice, 64% (9 out of 14) of Bhmt-/- 
mice and 0% (0 out of 11) of Bhmt+/+ mice had visible hepatic tumors (Figure 3.4a). Tumors 
observed in Bhmt-/- mice were solitary or multifocal, found in multiple liver lobes. The 
average liver weight of Bhmt-/- mice was heavier than that of Bhmt+/+ mice (6.22 ± 2.11 
%BW in Bhmt-/- vs 4.36 ± 0.26 %BW in Bhmt+/+; p<0.001), attributable to tumor mass. A 
subset of the liver samples (4 out of 11 Bhmt+/+ livers, 6 out of 9 Bhmt-/- livers with tumors, 
and 4 out of 5 Bhmt-/- livers without tumors) were serial-sectioned entirely, stained with H&E, 
and send to two veterinary pathologists for diagnosis. Microscopic analysis depicted a series 
of histological abnormalities from preneoplastic lesions (acidophilic/eosinophilic cell foci) to 
frank neoplasia visible only in the Bhmt-/- mice (Table 3.4 & Figure 3.4b). Hepatocellular 
adenomas (HCA) were found in 30% (3 out of 10) of the analyzed Bhmt-/- livers and none 
were found in the control animals. These benign lesions were represented by single or 
multiple nodules, sharply demarcated from the surrounding tissues, with a mild to moderate 
compression border and loss of lobular structure. Hepatocellular carcinomas (HCC) were 
found in 50% (5 out of 10) of the analyzed Bhmt-/- livers. HCC were represented by nodules 
of atypical, megalo-hepatocytes that were vacuolated or contained hyaline droplets. 
Indicative of malignancy, these lesions were organized in cords that were 5-6 cells wide, had 
poor or nonexisting interface with the surrounding tissues, and compressed mildly the 
adjacent normal cords. The portal triads and sinusoids were poorly or non-distinguishable in 
most of the nodules. Formation of HCA and HCC in Bhmt-/- mice were accompanied by 
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macro and micro vesicular steatosis, and stellate (Ito) cell and/or oval (bililary) cell 
hyperplasia (Table 3.4). We did not study Bhmt+/- mouse survival or carcinogenesis. 
 
Bhmt deletion resulted in elevated gamma glutamyltransferase 1 in livers - gGT1 is a 
highly sensitive marker of chronic liver disease, neoplasia. and HCC [214]. Bhmt-/- mice had 
hepatic gGT1 concentrations 3.3 fold higher than that of the control mice (0.815 ± 0.049 
ng/mg tissue in Bhmt-/- vs 0.245 ± 0.085 ng/mg tissue in Bhmt+/+; p<0.01). 
 
Changes in choline and one-carbon metabolites at 5 weeks persisted at 1 year old Bhmt-
/- mice - Choline deficiency and reduced methylation potential have been hypothesized as 
mechanisms underlying development of HCC. Compared to wildtype mice, Bhmt-/- mice had 
a 91% reduction in hepatic methylation potential (AdoMet:AdoHcy) compared to Bhmt+/+ 
mice (p<0.001) at 1 year (Table 3.5), which was greater than the 76% reduction seen at 5 
weeks of age (Table 3.2). The reduced methylation potential was due to reduced hepatic 
AdoMet (by 50%; p<0.01) and to elevated AdoHcy (by 5.5 fold; p<0.001) concentrations in 
Bhmt-/- mice compared to Bhmt+/+ mice. Compared to wildtype littermates, Bhmt-/- mice had 
a 30-fold increase in hepatic betaine, a 73% reduction in GPCho, a 64% reduction in PCho, 
and an 18.8% reduction in PtdCho concentrations. At 1 yr old, Bhmt-/- mice still had elevated 
plasma tHcy concentration (by 6.9-fold; p<0.01), but no longer had decreased plasma 
cysteine concentration.            
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3.5 DISCUSSION 
 
To our knowledge, this is the first report of the successful creation of Bhmt-/- mice. 
Deletion of Bhmt gene resulted in the complete loss of BHMT activity in liver, the organ 
where nearly all of activity resides in mice. Heterozygous mice had 53% of the hepatic 
BHMT activity measured in Bhmt+/+, suggesting that the Bhmt gene is biallelically expressed. 
Mating pairs of Bhmt+/+, Bhmt+/-, and Bhmt-/- produced offspring with normal number of 
pups and evenly distributed genders, suggesting that BHMT is not essential for reproduction. 
This is interesting because mice in which choline dehydrogenase (Chdh; form betaine from 
choline, immediately upstream from Bhmt in choline pathway, Figure 3.5) was deleted are 
infertile [215]. Fetuses from heterozygous (Bhmt+/-) mating pairs were born at the expected 
Mendelian ratio; they were viable and survived to at least one year of age, suggesting that 
BHMT is not essential for embryonic development or for the viability of mice.  
 
Though a Bhmt knockout mouse has not been previously created, when S-(δ-
carboxybutyl)-DL-homocysteine (CBHcy; a potent and specific inhibitor of BHMT) was 
administered intraperitoneally to wildtype mice [109] or fed to rats [110], it caused an 
elevation of plasma Hcy concentrations and a reduction in hepatic AdoMet:AdoHcy ratio. 
Our current study confirms the finding that inhibiting or ablating flux through BHMT affects 
one carbon metabolism. The changes are summarized in Figure 3.5. As expected, Bhmt-/- 
mice had significantly higher concentrations of the substrates for this enzyme (betaine and 
Hcy) in various tissues as compared to Bhmt+/+ mice. Our data show that the transsulfuration 
and methionine synthase pathways do not have the capacity to remove the excess tHcy that 
 48 
 
accumulates when BHMT is not present, indicating that BHMT has a critical role in Hcy 
homeostasis. Bhmt-/- mice also had a significant reduction in hepatic dimethylglycine 
concentrations, one of the products of BHMT.  Methionine, the other reaction product, was 
not affected by the gene deletion, probably because dietary methionine and protein stores of 
methionine are so large that the loss of BHMT-catalyzed biosynthesis does not alter overall 
concentrations of this amino acid.  However, AdoMet concentration, which is formed from 
methionine, was reduced in livers of Bhmt-/- mice, while AdoHcy concentrations were 
elevated.  AdoMet is used by glycine N-methyltransferase (GNMT), to form methylglycine 
from glycine [216] (Figure 3.5). Methylglycine is also formed from dimethylglycine, the 
product of the BHMT catalyzed reaction. Since Bhmt-/- mice do not accumulate 
dimethylglycine, the elevated methylglycine observed in Bhmt-/- mice likely comes from the 
action of GNMT. GNMT is allosterically inhibited by methylTHF [198], which serves as the 
methyl-donor for methionine synthase, a parallel pathway to BHMT that catalyzes the 
conversion of Hcy to methionine [195]. It is possible that the Bhmt-/- mice rely heavily on the 
use of methylTHF to form the needed methionine. Hence, GNMT is released from 
methylTHF inhibition, resulting in increased methylglycine, reduced AdoMet and increased 
AdoHcy concentrations that we observed. This hypothesis is supported by elevated hepatic 
GNMT activity in Bhmt-/- mice (Figure 3.2), as well as the reduction in plasma 
concentrations of total folate (the predominant form contributing to plasma total folate is 
methylTHF) (Table 3.2). AdoHcy is cleaved by AdoHcy hydrolase, producing Hcy and 
adenosine. This reaction is reversible and thermodynamically favors the synthesis of AdoHcy 
[217]; this should occur in  the presence of the high tHcy concentrations present in the Bhmt-/- 
mice. 
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Despite high plasma tHcy concentrations, Bhmt-/- mice had significantly lower plasma 
cysteine concentrations; we observed no differences in hepatic cysteine concentrations. 
Normally, high Hcy would be expected to result in increased cystathionine and cysteine 
concentrations. For example, MTHFR deficient mice had elevated plasma Hcy, accompanied 
by elevated plasma cysteine [218]. Supplemental betaine has been shown to increase the 
activity of liver CBS [219], thus the accumulation of this metabolite as well as tHcy in Bhmt-
/- mice would be expected to increase concentrations of cysteine. However, AdoMet is an 
allosterically activator of CBS [220], and we suggest that reduced hepatic AdoMet 
concentrations inhibit the transsulfuration pathway. The flux of cysteine from liver to plasma 
must be rapid, perhaps explaining why plasma and not hepatic cysteine concentrations are 
altered.   
 
Deletion of Bhmt results in a substantial accumulation of betaine in most tissues 
except testis. Betaine is either used as a methyl donor (which is blocked by Bhmt deletion) or 
as an osmolyte that regulates cellular volume and fluid balance. The accumulation of betaine 
in Bhmt-/- mice may affect osmoregulation. Tests of kidney function did not reveal any 
malfunction (Table 3.3). However, Bhmt-/- mice had reduced urinary specific gravity (USG) 
compared to that of Bhmt+/+ mice (Table 3.3), suggesting reduced reabsorption of water by 
the kidney tubule. This finding is puzzling since high betaine should result in increased 
reabsorption of water and increased urine osmolality.   
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Surprisingly, the deletion of Bhmt does not result in accumulation of choline, the 
precursor of betaine. Choline is either oxidized to form betaine by the enzyme CHDH or it is 
used to form PtdCho. Since Bhmt-/- mice cannot utilize betaine, we expected to see product 
inhibition of CHDH resulting in increased choline availability for use in PtdCho synthesis. 
We observed the opposite, with lower choline and PtdCho concentrations in a number of 
tissues. Bhmt-/- mice had elevated hepatic expression of Chdh (data not shown) and hepatic 
CHDH activity (Figure 3.2), suggesting that this gene is induced by some factor in Bhmt-/- 
mice, possibly explaining increased use of choline to form betaine. The regulatory 
mechanisms for such an effect are not known.  
 
At 5 weeks of age, Bhmt-/- mice developed a fatty liver, and had elevated plasma ALT 
activity (a measure of hepatic damage). The fatty liver is the result of decreased synthesis of 
PtdCho, which is essential for the secretion of VLDL from liver [221]. These findings are 
consistent with the literature. Rodents and humans fed a choline deficient diet develop fatty 
liver [222, 223], and have elevated plasma ALT activity because choline deficiency induces 
hepatocytes apoptosis [35]. Consistent with these observations in Bhmt-/- mice, others have 
reported administration of betaine or the induction of BHMT activity prevents fatty liver in 
Mthfr-/- mice [218], in non-alcoholic fatty liver [107] and in alcohol induced fatty livers [91, 
100] in rodents. Together, these data suggest the importance of BHMT activity in modulating 
hepatic steatosis. In addition, Bhmt-/- mice had reduced plasma total cholesterol and HDL-C. 
The role of Bhmt deletion in cholesterol and lipoprotein homeostasis warrants further studies.  
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At 1 year of age, 64% of Bhmt-/- mice developed hepatic tumors. Histopathology 
confirmed that these tumors were either hepatocellular adenomas or carcinomas. Even those 
that did not have visible tumors had higher incidence of fat accumulation, cellular alteration 
and hyperplasia when compared to Bhmt+/+ livers. Histological modifications were 
accompanied by elevation in gGT1 levels, a highly sensitive marker of HCC. In rodents, 
choline deficiency results in a higher incidence of spontaneous hepatocellular carcinomas 
[112]. Several mechanisms are suggested for these carcinogenic effects. Choline deficiency 
increases lipid peroxidation in the liver [113], which is a source of free radicals in the 
nucleus that could modify DNA and cause carcinogenesis. Choline deficiency perturbs 
protein kinase C (PKC) signaling, resulting in altered cell proliferation signals and cell 
apoptosis and eventually in carcinogenesis [114]. Methyl deficiency may also mediate the 
mechanisms that underlie the etiology of cancers. AdoMet level controls cell growth, and a 
persistent decrease in AdoMet concentrations leads to the development of HCC as observed 
in methionine adenosyltranferase 1A knockout mouse model (cannot make AdoMet from 
Met) [121]. Methyl deficiency may also alter epigenetic machinery by hypomethylating some 
genes but paradoxically hypermethylating specific genes (tumor suppressor genes) and 
consequently increasing the recruitment of methyl-binding proteins to the CpG islands. 
Consequently, the expression of tumor suppressor genes responsible for DNA repair 
(BRCA1, hMLH1), cell cycle regulation (p15, p16), carcinogenesis metabolism (GSTP1), 
hormonal response (RARβ2), apoptosis (DAPK, APAF-1), cell adherence (CDH1, CDH3) 
[118-120] are silenced, leading to tumor development. All the above mechanisms are 
potentially the underlying causes of HCC observed in Bhmt-/- mice since these mice are 
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essentially choline and methyl-group deficient. We plan to investigate each of these 
hypotheses in ongoing work in our laboratory.  
 
Hepatocellular carcinoma is the fifth most common type of cancer worldwide [224]. 
In mouse models harboring genetic defects, HCC occurs spontaneously in a very limited 
number of cases [225]. For the first time, we present evidence that the Bhmt gene dysfunction 
links a metabolic defect to spontaneous neoplastic transformation in rodent livers. Bhmt-/- 
mice model marks the upper boundary for an effect of a lost-of-function gene variant in 
humans. Our studies in the Bhmt-/- mice suggest that humans with lost-of-function mutation 
in the BHMT gene may have important consequences, including hyperhomocysteinemia, 
altered choline metabolites, fatty liver, and hepatocellular carcinomas. It would be interesting 
to explore whether enhanced BHMT activity would reverse these symptoms.
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3.6 FIGURES 
 
Figure 3.1. Confirmation of Bhmt-/- mice.  
A. Bhmt chimeric mice were generated using a gene targeting vector that removed exons 6 
and 7 of the gene as described under “Experimental Procedures”. loxP, locus of X-over P1; 
frt, flippase recognition target; neo, neomycin cassette; flp, flippase recombination enzyme; 
cre, cyclization recombination enzyme. B. PCR analysis of genomic DNA isolated from 
Bhmt+/+, Bhmt+/-, and Bhmt-/- mice. The PCR product of the WT allele was 1600 bp, while the 
KO allele was 545 bp. C. Hepatic BHMT activity was measured using a radiometric assay in 
Bhmt+/+ (black bar), Bhmt+/- (hatched bar), and Bhmt-/- (white bar) mice. Data are presented 
as mean ± SEM, n=4-8 per group. Different letters differ significantly (p<0.01) by ANOVA 
and Tukey-Kramer HSD test. D. BHMT protein in liver from Bhmt+/+ and Bhmt-/- mice were 
probed by Western blot analysis. The size of BHMT protein is 45 kDa. E. Body weights of 
Bhmt+/+ (black square), Bhmt+/- (grey square), and Bhmt-/- (white square) mice were measured 
using a scale from age 3.5 to 20 weeks old. Data are presented as mean ± SEM, n=10-25 per 
group.*p<0.05, different from Bhmt+/+ by Students’ t test.   
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Figure 3.2. Bhmt-/- mice have altered activities of enzymes involved in one-carbon 
metabolism.  
CHDH, GNMT and PEMT activities were measured in 5 week old Bhmt+/+ (black bar) and 
Bhmt-/- mice (white bar) mouse liver using radiometric assays. Data are presented as mean ± 
SEM, n=6-8 per group. *p<0.05, different from Bhmt+/+ by Students’ t test. CHDH, choline 
dehydrogenase; GNMT, glycine-N-methyltransferase; PEMT, phosphatidylethanolamine 
methyltransferase. 
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Figure 3.3. Bhmt-/- mice have fatty liver and reduced hepatic phospholipid 
concentrations.  
A. Hepatic phospholipids of 5 week Bhmt+/+ (black bar) and Bhmt-/- mice (white bar) mice 
were analyzed by a thin layer chromatography - phosphate assay method. Data are presented 
as mean ± SEM, n=5 per group. *p<0.01, different from Bhmt+/+ by Students’ t test. B. 
Morphology of liver from 5 week old mice was shown by hematoxylin-eosin (H&E) staining 
at 100X magnification. Scale bar = 50 µm. C. Hepatic TAG of 5 week old Bhmt+/+ (black bar) 
and Bhmt-/- (white bar) mice was extracted and quantitated by a colorimetric assay. Data are 
presented as mean ± SEM, n=6-8  per group. *p<0.05, different from Bhmt+/+  by Students’ t 
test. D. VLDL secretion rate of 5 week old Bhmt+/+ (black square) and Bhmt-/- (white square) 
mice was determined by measuring the plasma TAG after lipoprotein lipase inhibitor 
injection. Data are presented as mean ± SEM, n=6 per group. *p<0.05, different from 
Bhmt+/+ by Students’ t test. TAG, triacylglycerol; PLs, phospholipids; PtdCho, 
phosphatidylcholine; PtdEth, phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdSer, 
phosphatidylserine; VLDL, very low density lipoprotein 
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Figure 3.4. Bhmt deletion results in liver tumors at 1 year of age.  
A. Visible hepatic tumors in one year old Bhmt-/- male mice. The inspection of liver 
specimens at 4X magnification revealed single or multiple nodules up to 8 mm in diameter.  
B. H&E images of tumor bearing livers at 400X magnification, showing representative 
hepatocellular carcinoma and adenoma morphology. Scale bar = 50 µm. 1. Regenerative 
hyperplastic nodule containing streams of proliferative oval and biliary cells; 2. 
Hepatocellular adenoma (* - center of the nodule) well-circumscribed with lobular structure 
absent, compressive borders, eosinophilic hepatocytes; 3. Hepatocellular carcinoma 
represented by a large mass of abnormal vacuolated hepatocytes, containing poorly 
demarcated areas of smaller hepatocytes with less vacuolization, amphophilic cytoplasm, and 
a streaming growth pattern (arrow); 4. Hepatocellular carcinoma nodule of variably sized 
hepatocytes exhibiting cytomegaly with hyaline droplets, small hepatocytes with streaming 
growth pattern, oval cell proliferation, Ito cell proliferation between cords (unlabeled arrow), 
infiltration of leukocytes.   
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Figure 3.5. Changes in one-carbon metabolism due to Bhmt deletion.  
Deletion of Bhmt resulted in changes in the concentrations of the metabolites or activities of 
enzymes involved in homocysteine and one-carbon metabolism in tissues. AdoMet, S-
adenosylmethionine; AdoHcy, S-adenosylhomocysteine; PtdCho, phosphatidylcholine; 
PtdEth, phosphatidylethanolamine; BHMT, betaine homocysteine methyl-transferase; PEMT, 
phosphatidylethanolamine methyltransferase; GNMT, glycine methyltransferase; CHDH, 
choline dehydrogenase. 
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3.7 TABLES 
Table 3.1. Deletion of Bhmt results in altered choline metabolites in various tissues. 
Tissues were harvested from 5 week old Bhmt+/+ and Bhmt-/- mice. Choline metabolites were extracted and quantified by liquid 
chromatography-electrospray ionization-isotope dilution mass spectrometry (LC–ESI–IDMS). Data are presented as mean ± SEM, 
n=5-10 animals/group. *p<0.05, ¥p<0.01,£p<0.001 different from Bhmt+/+ by Students’ t test. Concentrations are expressed as nmol/g, 
except for plasma, which is nmol/ml.  PCho, phosphocholine; PtdCho, phosphatidylcholine; GPho, glycerophosphocholine; 
SM,sphingomyelin; ND, not detected. 
 
  Betaine Choline GPCho PCho PtdCho SM 
Liver Bhmt+/+  1,321 ± 254 154 ± 36 1,730 ± 554  294 ± 67 15,897 ± 1,200 1,018 ± 131
 Bhmt-/- 27,314 ± 2,001£ 28 ± 8¥ 266 ± 38¥  81 ± 7¥ 11,686 ± 305¥ 838 ± 37
Kidney Bhmt+/+  1,151 ± 91 779 ± 60 15,608 ± 1,475  853 ± 37 16,088 ± 1,025 3,373 ± 277
 Bhmt-/-  5,424 ± 505£ 481 ± 48¥ 10,948 ± 672*  792 ± 41 12,707 ± 304* 2,685 ± 74*
Heart Bhmt+/+  77 ± 11 84 ± 12 164 ± 7  199 ± 12 11,111 ± 535 879 ± 50
 Bhmt-/-  1,070 ± 131£ 49 ± 6* 88 ± 10£  151 ± 14* 8,381 ± 455¥ 583 ± 44£
Brain Bhmt+/+  22 ± 2 183 ± 26 1,208 ± 52  579 ± 33 22,856 ± 1,147 2,191 ± 149
 Bhmt-/-  100 ± 10£ 174 ± 15 1,120 ± 57  502 ± 9 21,020 ± 271 1,834 ± 52
Muscle Bhmt+/+  44 ± 3 67 ± 15 67 ± 4  51 ± 6 7,893 ± 655 411 ± 15
 Bhmt-/-  529 ± 36£ 28 ± 3* 58 ± 6  18 ± 3£ 5,942 ± 238* 390 ± 13
Adipose Bhmt+/+  142 ± 25 73 ± 12 802 ± 223  90 ± 6 2,500 ± 217 156 ± 14
 Bhmt-/-  284 ± 18£ 34 ± 5¥ 246 ± 79*  29 ± 7* 2,288 ± 271 144 ± 18
Lung Bhmt+/+  206 ± 17 198 ± 24 3,586 ± 348  551 ± 26 14,693 ± 344 2,389 ± 65
 Bhmt-/-  2,237 ± 123£ 188 ± 23 2,063 ± 82£  465 ± 42 14,437 ± 192 2,387 ± 47
Plasma Bhmt+/+  48 ± 3 20 ± 4 ND ND 1,590 ± 81 145 ± 10
 Bhmt-/-  772 ± 173£ 13 ± 2 ND ND 1,098 ± 71£ 114 ± 77
Testis Bhmt+/+  2,014 ± 312 298 ± 51 809 ± 26 3,831 ± 270 5,760 ± 387 886 ± 74
 Bhmt-/-  2,018 ± 111 241 ± 10 565 ± 47 3,706 ± 234 5,942 ± 233 954 ± 38
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Table 3.2. Deletion of Bhmt results in reduced methylation potential and increased 
homocyteine concentrations.  
Tissues were harvested from 5 week old Bhmt+/+ and Bhmt-/- mice. Hepatic homocysteine 
metabolites were quantified by capillary stable isotope dilution gas chromatography/mass 
spectrometry. Hepatic AdoMet, AdoHcy and plasma total homocysteine and cysteine were 
quantified by high pressure liquid chromatography. Plasma total folate was quantified by a 
microbial (Lactobacillus casei) assay. Data are presented as mean± SEM, n=5-6 per group. 
*p<0.05, **p<0.01, different from Bhmt+/+ by Students’ t test. AdoMet, S-
adenosylmethionine; AdoHcy, S-adenosylhomocysteine. 
 
 
 
Organ Metabolites Bhmt+/+ Bhmt-/-
Liver AdoMet [nmol/g tissue] 76.4 ± 3.7  43.5 ± 5.7**
 AdoHcy [nmol/g tissue] 21.8 ± 1.7  54.4 ± 7.7**
 AdoMet:AdoHcy 3.6 ± 0.2  0.9 ± 0.1**
 tHomocysteine [nmol/g tissue] 4.2 ± 0.3  26.5 ± 5.5**
 Methionine [nmol/g tissue] 223 ± 26  242 ± 23
 Dimethylglycine [nmol/g tissue] 48.2 ± 19.0  2.2 ± 0.2**
 Methylglycine [nmol/g tissue] 20.2 ± 8.9  52.7 ± 12.2*
 Cystathionine [nmol/g tissue] 32.0 ± 15.7  20.3 ± 5.8
 Cysteine [nmol/g tissue] 247 ± 25  291 ± 25
 Glycine [nmol/g tissue] 1,659 ± 128  1,561 ± 135
Plasma tHomocysteine [µM] 6.5 ± 0.7  50.8 ± 5.9**
 Cysteine [µM] 131.1 ± 9.9  68.4 ± 9.3**
 tFolate [ng/ml] 81.7 ± 6.4  52.8 ± 5.1**
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Table 3.3. Deletion of Bhmt results in altered metabolic markers 
Plasma was collected from 5 week old Bhmt+/+ and Bhmt-/- mice after 4 h fasting. 
Concentrations of plasma ALT, BUN, creatinine and activities of LDH and CK were 
quantitated by the Animal Clinical Chemistry and Gene Expression Facility, UNC-Chapel 
Hill. Plasma triacylglycerol, cholesterol, HDL cholesterol, glucose, NEFA, hydroxybutyrate 
were measured colorimetrically. Urine specific gravity was measured by the Department of 
Laboratory Animal Medicine Veterinary and Technical Services Facility, UNC- Chapel Hill. 
Data are presented as mean ± SEM, n=5-7 per group. *p<0.05, **p<0.01, different from 
Bhmt+/+ by Students’ t test. ALT, alanine transaminase; BUN, plasma urea nitrogen; LDH, 
lactate dehydrogenase; CK, creatinine kinase; HDL-C, high density lipoprotein cholesterol; 
NEFA, non-esterified fatty acids. 
 
Organ Clinical Markers Bhmt+/+ Bhmt-/-
Plasma ALT [U/I] 20.6 ± 4.9  34.7 ± 4.4*
 BUN [mg/dL] 12.5 ± 0.8  13.0 ± 1.8
 Creatinine [mg/dL] <0.1  <0.1 
 LDH [U/I] 841 ± 67  689 ± 80
 CK [U/I] 741 ± 147  511 ± 147
 Triacylglycerol [mg/dL] 60.9 ± 7.7  47.2 ± 7.9
 Cholesterol [mg/dL] 57.8 ± 4.3  31.6 ± 4.3**
 HDL-Cholesterol [mg/dL] 45.8 ± 3.2  26.7 ± 5.7**
 Glucose [mg/dL] 292.5 ± 33.2  226.0 ± 15.9
 NEFA [mM] 0.44 ± 0.08  0.28 ± 0.07
 Hydroxybutyrate [mM] 0.39 ± 0.08  0.29 ± 0.03
Urine Specific Gravity [mg/dL] 1.039 ± 0.005  1.020 ± 0.002**
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Table 3.4. Pathology in livers from a subset of 1 year old Bhmt+/+ and Bhmt-/-mice. 
A subset of 1 year old Bhmt+/+ (4 out of 11, none had visible tumors) and Bhmt-/- mouse liver 
(6 out of 9 that had visible tumors, 4 out of 5 that did not have visible tumors) were serial-
sectioned, H&E stained, and send to 2 veterinary pathologists for diagnosis. Dots indicated 
the changes observed in a particular sample. HCA, hepatocellular adenoma; HCC, 
hepatocellular carcinoma; Fat Accu., fat accumulation. 
 
Genotype Visible 
Tumor 
HCA HCC Fat 
Accu.
Cellular 
Alteration 
Hyperplasia
Bhmt+/+  • • 
Bhmt+/+  
Bhmt+/+  
Bhmt+/+  
Bhmt-/- • • • • •
Bhmt-/- • • • • •
Bhmt-/- • • • •
Bhmt-/- • • • 
Bhmt-/- • • • •
Bhmt-/- • •
Bhmt-/-  • • •
Bhmt-/-  • 
Bhmt-/-  •
Bhmt-/-  • 
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Table 3.5. Metabolites in 1-yr-old mouse tissues 
Tissues were harvested from 1 year old Bhmt+/+ and Bhmt-/- mice. Hepatic AdoMet, AdoHcy 
and plasma homocysteine and cysteine were quantified by high pressure liquid 
chromatography. Choline metabolites were extracted and quantified by liquid 
chromatography-electrospray ionization-isotope dilution mass spectrometry (LC–ESI–
IDMS). Data are presented as mean± SEM, n=8 per group. **p<0.01, different from Bhmt+/+ 
by Students’ t test. AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; 
GPCho, glycerophosphocholine; PC, phosphocholine; PtdCho, phosphatidylcholine; SM, 
sphingomyeline. 
 
Organ Metabolites Bhmt+/+ Bhmt-/- 
Liver AdoMet [nmol/g tissue] 113.1 ± 14.7  56.8 ± 3.9**
 AdoHcy [nmol/g tissue] 31.9 ± 5.3  176.3 ± 22.1**
 AdoMet:AdoHcy 4.05 ± 0.65  0.35 ± 0.03**
 Betaine [nmol/g tissue] 1,158 ± 330 34,976 ± 2,700**
 Choline [nmol/g tissue] 84 ± 13  144 ± 26 
 GPCho [nmol/g tissue] 803 ± 121  218 ± 21**
 PC [nmol/g tissue] 674 ± 90  243 ± 59**
 PtdCho [nmol/g tissue] 17,317 ± 683 14,075 ± 795**
 SM [nmol/g tissue] 1,788 ± 127  1,976 ± 85 
Plasma tHomocysteine [µM] 5.5 ± 0.7  37.7 ± 8.6**
 Cysteine [µM] 150.8 ± 17.4  134.6 ± 23.1
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3.8 SUPPLEMENTS 
 
Table 3.6. Choline metabolites in Bhmt+/- tissues 
Tissues were harvested from 5 week old Bhmt+/- mice. Data are presented as mean ± SEM, n=6 animals. *p<0.05, different from 
Bhmt+/+ by Students’ t test. Concentrations are expressed as nmol/g. PCho, phosphocholine; PtdCho, phosphatidylcholine; GPho, 
glycerophosphocholine; SM,sphingomyelin; ND, not detected. Choline metabolites in adipose and plasma were not measured in 
Bhmt+/- mice. 
 
 
 Betaine Choline GPCho PCho PtdCho SM 
Liver 1,923 ± 364   154 ± 36 1,730 ± 554 294 ± 67  15,897 ± 1,200 1,018 ± 131 
Kidney 1,296 ± 192   834 ± 28 15,786 ± 748 885 ± 31  14,035 ± 420 2,768 ± 60 
Heart     95 ± 29   102 ± 7 212 ± 65 193 ± 13   9,877 ± 471 738 ± 48 
Muscle  49 ± 4   67 ± 15 84 ± 10 41 ± 8  6,388 ± 174* 397 ± 11 
Brain     18 ± 2   197 ± 36 1,322 ± 58 588 ± 35  20,441 ± 402 1,869 ± 84 
Lung  239 ± 26   224 ± 26 3,432 ± 203  588 ± 20  14,777 ± 343 2,415 ± 63 
Testis 2,334 ± 239    439 ± 30 859 ± 157 4,495 ± 193   6,581 ± 490 1,039 ± 61 
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Table 3.7. Other metabolites in Bhmt+/- tissues 
Tissues were harvested from 5 week old Bhmt+/- mice. Data are presented as mean± SEM, 
n=3-6 per group. *p<0.05, different from Bhmt+/+ by Students’ t test. #p<0.05, different from 
Bhmt-/- by Students’ t test. AdoMet, S-adenosylmethionine; AdoHcy, S-
adenosylhomocysteine. ALT, alanine transaminase; BUN, plasma urea nitrogen; LDH, 
lactate dehydrogenase; CK, creatinine kinase; HDL-C, high density lipoprotein cholesterol; 
NEFA, non-esterified fatty acids. 
 
Organ Metabolites Bhmt+/-
Liver AdoMet [nmol/g tissue] 86.3 ± 22.8 
 AdoHcy [nmol/g tissue] 35.4 ± 12.1
 AdoMet:AdoHcy 2.9 ± 0.4 
Plasma tHomocysteine [µM] 6.3 ± 0.3 
 Cysteine [µM] 102.6 ± 8.4*#
 Total folate [ng/ml] 81.3 ± 17.7
 ALT [U/I] 31.0 ± 1.6 
 BUN [mg/dL] 13.55 ± 0.3
 Creatinine [mg/dL] <0.1 
 LDH [U/I] 917.3 ± 165.5
 CK [U/I] 793.3 ± 51.3 
 Triacylglycerol [mg/dL] 71.2 ± 5.8
 Cholesterol [mg/dL] 48.7 ± 20.1
 HDL-Cholesterol [mg/dL] 37.9 ± 14.9
 Glucose [mg/dL] 259.1 ± 13.1
 NEFA [mM] 0.29 ± 0.04
 Hydroxybutyrate [mM] 0.39 ± 0.02
 
 
 
 
  
 
 
 
 
CHAPTER IV 
THE ROLE OF BHMT IN ENERGY HOMEOSTASIS 
 
MOUSE BETAINE-HOMOCYSTEINE S-METHYLTRANSFERASE DEFICIENCY 
REDUCES BODY FAT VIA INCREASING ENERGY EXPENDITURE AND IMPAIRING 
FUEL USAGE AND STORAGE1 
 
Ya-Wen Teng, Jessica M. Ellis, Rosalind A. Coleman, and Steven H. Zeisel 
 
 
4.1 ABSTRACT 
 
Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the synthesis of methionine 
from homocysteine. In our initial report, we observed a reduced body weight in Bhmt-/- mice. 
We initiated this study to investigate the potential role of BHMT in energy metabolism. 
Compared to the controls (Bhmt+/+), Bhmt-/- mice had less fat mass, smaller adipocytes, and 
better glucose and insulin sensitivities. 
______________________________ 
1Teng, Y., Ellis, J.M., Coleman, R.A., and Zeisel, S.H. (2011). Deletion of Murine Betaine-
Homocysteine S-Methyltransferase Results in Decreased Body Fat Via Altering Energy 
Metabolism. Under Revision in JBC.    
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Compared to the controls, Bhmt-/- mice had increased energy expenditure and respiratory 
exchange ratio, with no changes in food intake, fat uptake or absorption, or in locomotor 
activity. The reduced adiposity in Bhmt-/- mice was not due to hyperthermogenesis. Bhmt-/- 
mice failed to maintain a normal body temperature upon cold exposure. In vivo and ex vivo 
tests showed that Bhmt-/- mice had normal lipolytic function. The rate of [14C] fatty acid 
incorporated into [14C] triacylglycerol was the same in Bhmt+/+ and Bhmt-/- gonadal fat depots 
(GWAT), but was 62% lower in Bhmt-/- inguinal fat depots (IWAT) compared to that of 
Bhmt+/+mice. The rate of [14C] fatty acid oxidation was the same in both GWAT and IWAT 
from Bhmt+/+ and Bhmt-/- mice. At basal level, Bhmt-/- GWAT had the same [14C] glucose 
oxidation as did the controls. When stimulated with insulin, Bhmt-/- GWAT oxidized 2.4-fold 
more glucose than did the controls. Compared to the controls, the rate of [14C] glucose 
oxidation was 2.4 and 1.8 fold higher respectively in Bhmt-/- IWAT without or with insulin 
stimulus. Our results show for the first time a role for BHMT in energy homeostasis.   
 
4.2 INTRODUCTION 
 
Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the formation of 
methionine from homocysteine using the choline metabolite betaine as the methyl donor. 
BHMT is an enzyme predominantly found in liver in rodents [18], and plays an essential role 
in regulating homocysteine, choline, and one-carbon metabolism. BHMT also influences 
hepatic lipid accumulation via altering phosphatidylcholine (PtdCho) concentration. BHMT 
exerts this effect through two mechanisms. Firstly, choline, the precursor of betaine, can 
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alternatively be used to make PtdCho via Kennedy pathway. Secondly, methionine, the end 
product of BHMT, is the precursor of S-adenosylmethionine (AdoMet), which is required for 
the synthesis of PtdCho from phosphatidylethanolamine (PtdEtn) by the enzyme PtdEtn 
methyltransferase (PEMT). BHMT overexpression increases PtdCho synthesis, leading to 
reduced hepatic lipid accumulation [95], while BHMT deficiency leads to fatty liver [226]. 
While the role of BHMT in hepatic lipid metabolism has been elucidated, there is no 
evidence that BHMT plays a role in whole body energy metabolism and adiposity.  
 
We observed that Bhmt deficient (Bhmt-/-) mice had a lower body weight from 5 to 9 
weeks of age compared to wildtype littermates [226]. Magnetic resonance image (MRI) 
analysis and dissection of adipose fat depots revealed that the reduced body weight observed 
in Bhmt-/- mice was due to reduced fat depots. These results suggested that Bhmt deficient 
mice might have problems with whole-body energy and lipid metabolism. This study aims to 
investigate the metabolic perturbations that lead to the reduced adiposity observed in Bhmt-/- 
mice. Homeostasis of energy stores is regulated by mechanisms including modulation of 
metabolic rate and thermogenesis, control of metabolite fluxes among various organs, and 
modulation of fuel synthesis and use within adipose tissue. We present evidence that Bhmt-/- 
mice have reduced adiposity due to increased whole-body metabolic rate, impaired 
triglyceride synthesis and enhanced glucose oxidation in white adipose tissue (WAT). 
 
4.3 EXPERIMENTAL PROCEDURES 
 
Generation and Maintenance of Mice – The strategy used to generate Bhmt-/- mice was as 
previously described [226]. Bhmt-/- mice and their wildtype littermates were of a C57Bl/6 x 
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sv 129 genetic background and were continuously backcrossed to C57Bl/6 mice. Generations 
F3 to F5 were used in this study. The animals were kept in a temperature-controlled 
environment at 24°C and exposed to a 12 hr light and dark cycle. All animals received AIN-
76A pelleted diet with 1.1 g/kg choline chloride (Dyets, Bethlehem, PA). The Institutional 
Animal Care and Use Committee of the University of North Carolina at Chapel Hill 
approved all experimental protocols. 
 
BHMT Western Blot - Mice were anesthetized by inhalation of isoflurane (Hospira, Lake 
Forest, IL). Tissues were harvested, snap frozen, pulverized under liquid nitrogen and stored 
at -80oC until used. Western blot analysis was performed in liver and adipose homogenates 
as previously described [196]. 
 
Metabolic Studies - Body composition was determined in 14-wk-old mice by MRI 
(EchoMRI-100, Echo Medical Systems, LLC, Houston). Core temperature was measured in 
7-wk-old mice using a rectal probe thermometer (Thermalert TH-5, Physitemp, Clifton, NJ). 
Food intake, oxygen consumption (VO2), carbon dioxide release (VCO2), heat production, 
and locomotor activity were measured every 27 minutes from individually housed mice (7-
wk-old) using indirect calorimetry (TSE Systems, Germany) with an airflow of 0.25 liter/min. 
Locomotor activity was measured using infrared technology as the counts of three 
dimensional beam breaking (X total, Y total and Z total). Respiratory exchange ratio (RER) 
was calculated as VCO2/VO2. Mice were acclimated to the chambers for 24 hr, and data were 
collected during the following 24 hr. Stool samples were collected, and TAG was extracted 
using the Folch method [211] and measured colorimetrically (Sigma, St. Louis, MO). For 
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cold tolerance tests, 7-wk-old mice were fasted for 4 hr before being exposed to cold (4°C) 
without food or bedding. Core temperature was measured using a rectal probe thermometer 
(Thermalert TH-5) at baseline and every 15 min. Mice were removed from the cold-room 
when body temperature dropped below 28°C. 
 
Biochemical Assays – An oral fat load test was performed by gavaging 7-wk-old mice with 
10 µL/g B.W. olive oil after an overnight fast. Blood was collected retroorbitally at baseline, 
1, 2, 4, and 6 hr, and plasma triacylglycerol (TAG) was measured with a colorimetric assay 
(Sigma). Glucose and insulin tolerance tests were performed by intraperitoneally injecting 
either glucose (2.5 g/kg B.W.) or human insulin (1 U/kg B.W., Novo Nordisk Inc., Princeton, 
NJ) to 7-wk-old mice after a 6 or 4 hr fast, respectively. Blood glucose was measured at 
baseline, 15, 30, 60, and 120 min by tail nick using a glucometer (One Touch Ultra, LifeScan, 
Inc., Milpitas, CA).  
 
Plasma Metabolites - Plasma insulin (Ultra-Sensitive Mouse Insulin ELISA Kit, Crystal 
Chem Inc., Downers Grove, IL), total thyroxine (T4), total triiodothyronine (T3) (Alpha 
Diagnostic International, San Antonio, TX), and growth hormone (Millipore) levels were 
determined using commercially available ELISA kits according to the manufacturer’s 
protocol. Plasma fibroblast growth factor 21 (FGF21) was determined using an RIA kit 
(Phoenix Pharmaceuticals Inc., Burlingame, CA) according to the manufacturer’s protocol. 
Plasma creatine kinase (CK) was measured using an automatic chemical analyzer (Johnson 
and Johnson VT250, Rochester, NY) at the Animal Clinical Chemistry and Gene Expression 
Facility, UNC-Chapel Hill. Plasma TAG, glycerol (Sigma), and non-esterified fatty acids 
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(NEFA) (Wako, Richmond, VA) were measured colorimetrically per manufacturers’ 
instructions. Plasma glucose was measured using a glucometer (One Touch Ultra).  
 
Tissue Metabolites – Hepatic free glucose and glycogen were measured using an adopted 
acid hydrolysis method [227]. Liver was collected from 5-wk-old or 48-wk-old mice after a 4 
hr fast. Briefly, 40 mg pulverized liver was homogenized in 1 ml of 1N HCl. Half of the 
homogenate was neutralized with 0.5 ml of 1M NaOH (non-hydrolyzed group). The other 
half was incubated at 95°C for 90 min before being neutralized with NaOH (hydrolyzed 
group). Glucosyl units released in both groups were measured using a colorimetrical glucose 
kit (Wako). Non-hydrolyzed group represented the free glucose measurement, while the 
difference between the hydrolyzed and the non-hydrolyzed groups represented the glycogen 
measurement. For bile acids and steroids, liver and gonadal fat pads were collected from 5-
wk-old mice after a 4 hr fast. Tissues were sent to Metabolon (Research Triangle Park, NC), 
where the metabolites were measured using gas chromatography/mass spectrometry (GC/MS) 
and liquid chromatography/mass spectrometry (LC/MS) platforms as previously described 
[228-231]. Data was extracted and analyzed by Metabolon, and expressed as fold change 
relative to wildtype controls. For ATP/AMP/ADP, tissues were collected from 7-wk-old 
mice and immediately snap frozen in liquid nitrogen. Tissues were processed, and ATP, 
AMP and ADP measured using a high pressure liquid chromatography (HPLC) method as 
previously described [232].  
 
Reverse Transcription-PCR – Total RNA was isolated from tissue using RNeasy Mini kit 
(Qiagen, Valencia, CA), and cDNA was synthesized using high-capacity cDNA reverse 
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transcription kit (Applied Biosystems, Calsbad, CA). cDNA was amplified by real-time PCR 
using SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA) with primers specific to the gene 
of interest. Results were normalized to the housekeeping genes (cyclophilin A or GAPDH) 
and calculated relatively to the controls by the 2-∆∆CT method. For mitochondrial DNA 
analysis, genomic DNA was isolated by phenol/chloroform/isoamyl alcohol extraction. 
Relative amounts of mitochondria and nuclear DNA were determined by real-time PCR 
using cytochrome b and H19 respectively using genomic DNA as template.  
 
Lipolysis – For in vivo lipolysis, mice were injected intraperitoneally with lipolytic stimuli 
(10 mg isoproterenol/1 kg B.W. or 1 mg CL316243/1 kg B.W.) (Sigma). Plasma was 
collected retroorbitally at baseline and 1.5 hr after injection. Plasma glycerol (Sigma) and 
NEFA (Wako) were measured colorimetrically, and glucose measured using a glucometer 
(One Touch Ultra). Gonadal and inguinal adipose explants were used for ex vivo lipolysis 
measurement as previously described [233, 234]. Briefly, pieces of fat explants (20 mg) were 
incubated in 0.5 ml Krebs Ringer Buffer (KRB) (12 mM HEPES, 121 mM NaCl, 4.9 mM 
KCl, 1.2 mM MgSO4, and 0.33 mM CaCl2) supplemented with 3.5% fatty acid free bovine 
serum albumin (FFF-BSA) and 0.1% glucose with or without 10 µM isoproterenol at 37°C. 
Twenty-five µL of buffer was collected at various time points to measure the release of 
glycerol colorimetrically (Sigma).  
 
Adipocyte Isolation – Mature adipocytes were isolated from gonadal or inguinal fat depots 
from 12-16 wk-old mice and used for incorporation and oxidation studies [235]. Briefly, 
gonadal or inguinal fat depots were removed under sterile conditions, minced and incubated 
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at 37°C with shaking for 1 hr in KRB supplemented with 1% FFF-BSA, 2.5 mM glucose, 
and 200 nM adenosine, containing 1 mg/ml collagenase I. The digested tissues were filtered 
through a sterile 250 µm mesh and washed 3 times with supplemented KRB. Adipocytes 
were diluted with supplemented KRB to reach 10% adipocytes solution, and maintained for 
30 min in polypropylene tube before the start of the assay. Due to the small fat mass in Bhmt-
/- mice, the same fat depots from two Bhmt-/- mice were pooled together to get enough 
adipocytes per sample.    
 
Incorporation and Oxidation - For fatty acid incorporation into TAG, 500 µL of 10% 
adipocyte solution were incubated with a 125 µL reaction mixture containing 15 µM [1-14C] 
oleate (50 µCi/500 µL; Perkin Elmer) and 200 µM unlabeled oleate complexed to BSA for 2 
hr at 37°C. [14C] TAG was extracted [236], isolated by TLC, and detected and quantified 
with a Bioscan AR2000 Image System (Bioscan Inc., Washington, DC). The chromatoplate 
was run in chloroform/methanol/ammonium hydroxide (65:25:4; v:v:v) to 8 cm from the top. 
After residual solvents evaporated, the plate was rerun in heptane/isopropyl ether/acetic acid 
(60:40:4; v:v:v) to the top of the plate. For oxidation, 250 µL of 10% adipocytes solution 
were incubated with a 125 µL reaction mixture containing either 15 µM [1-14C] oleate and 
200 µM unlabeled oleate or 4 µM [14C] glucose (50 µCi/500 µl; Perkin Elmer) and 4 mM 
unlabeled glucose (in KRB) for 1.5 hr at 37°C. The reaction mixture was incubated in a 13 
mL polypropylene tube that contained a center well filled with folded filter paper. The tube 
was sealed with a rubber stopper. After 1.5 hr incubation, the reaction mixture was acidified 
with 150 µL of 70% perchloric acid, and 300 µL of 1 M NaOH was added to the center well. 
The sealed tubes were incubated at RT for an additional 45 min. The center well (containing 
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[14C] CO2 trapped by base) was then collected and placed into scintillation fluid and counted. 
The acidified reaction mixture (~400 µL) was incubated overnight at 4°C with 200 µL of 
20% BSA. The mixture was centrifuged at 13,200 rpm for 20 min, and an aliquot of the 
supernatant was counted to determine [14C]-labeled acid soluble metabolites (ASM). [14C] 
CO2 represents complete fatty acid or glucose oxidation, and [14C] ASM represents 
incomplete fatty acid oxidation. For some experiments, 0.01 U insulin (Novo Nordisk Inc., 
Princeton, NJ) was added. 
  
Tissue histology - Adipose tissues were collected from 12-wk-old mice and fixed in 4% 
paraformaldehyde in 0.1M phosphate buffer for 24 hr. Tissues were processed, paraffin 
embedded, sectioned at 5 µm, and stained with hemotoxylin and eosin as previously 
described [212]. For adipocyte size analysis, three images (200X) per sample were taken, and 
the average adipocyte cell areas were analyzed using AxioVision 4.8 software (Zeiss, USA). 
 
Statistics - Statistical differences were determined using ANOVA, Tukey-Kramer HSD, and 
Student’s t-test (JMP version 6.0; SAS Institute, Cary, NC) and reported as means ± SEM. 
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4.4 RESULTS 
 
BHMT Deficiency Resulted in Reduced Fat Mass and Smaller Adipocytes – Our 
previous publication reported that Bhmt-/- mice gained less body weight between 5 to 9 weeks 
of age than did their wildtype littermates (p<0.05) [226]. To determine whether the reduced 
weight gain of Bhmt-/- mice was associated with reduced fat or lean mass, we measured body 
composition of these mice using MRI scan analysis. Bhmt-/- mice had 30% less fat mass than 
did Bhmt+/+ mice (p<0.01), with no difference in lean mass (Figure 4.1A). The difference in 
fat mass was confirmed by collecting the individual fat pads. The two major white adipose 
tissues (WAT), gonadal (GWAT) and inguinal (IWAT), of Bhmt-/- mice were significantly 
smaller than those of Bhmt+/+ mice at all ages (Figure 4.1B). The disparity in fat mass was 
exacerbated as mice aged, such that by 48 weeks of age, Bhmt-/- mice had a fat mass that was 
41% of that of Bhmt+/+ mice. To determine whether the reduced fat mass in Bhmt-/- mice was 
due to fewer fat cells and/or smaller fat cells, the sizes of individual adipocytes in GWAT 
and IWAT of Bhmt+/+ and Bhmt-/- mice were analyzed. Histological images showed that both 
GWAT and IWAT from Bhmt-/- mice contained a larger number of smaller adipocytes 
(Figure 4.1C). We observed a 43% reduction in adipocyte size in GWAT (p<0.05) and an 
80% reduction in adipocyte size in IWAT (p<0.001) in Bhmt-/- mice compared to those of 
Bhmt+/+ mice (Figure 4.1D). These data suggested that Bhmt-/- mice likely had normal 
adipocyte differentiation, and that the Bhmt-/- adipocytes either stored less and/or used more 
lipids than did Bhmt+/+ adipocytes. Bhmt is predominantly expressed in rodent liver. Western 
blotting confirmed that BHMT protein was specific to the liver and was absent in the adipose 
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tissue from both Bhmt+/+ and Bhmt-/- mice (Figure 4.1E), suggesting that the reduced fat 
mass in Bhmt-/- mice was due to an indirect effect of the lack of hepatic BHMT activity. 
 
BHMT Deficiency Resulted in Enhanced Glucose Tolerance and Insulin Sensitivity - 
Changes in adiposity are often associated with alterations in glucose and insulin homeostasis. 
Bhmt-/- mice had normal basal blood glucose levels (Figure 4.1F, 4.1G). Upon 
intraperitoneal injection of either glucose (Figure 4.1F) or insulin (Figure 4.1G), Bhmt-/- 
mice exhibited a faster glucose removal rate than did wildtype controls. Bhmt-/- mice also had 
a basal plasma insulin concentration that was 50% of that of the controls (p<0.05) (Table 
4.1), indicating enhanced insulin sensitivity.  
 
Bhmt-/- Mice Had Increased Energy Expenditure – To investigate the mechanisms that 
elicit the reduced fat mass in Bhmt-/- mice, elements of energy metabolism, including food 
intake, lipid uptake and absorption, body temperature, energy expenditure and activity, were 
determined. Bhmt+/+ and Bhmt-/- mice consumed similar amounts of food per day (Figure 
4.2A). Fat load test (Figure 4.2B) and fecal lipid content (Figure 4.2C), tests for lipid uptake 
and absorption respectively, displayed no differences between Bhmt+/+ and Bhmt-/- mice. 
Bhmt+/+ and Bhmt-/- mice had similar rectal temperatures (Figure 4.2D). Compared to 
wildtype controls, Bhmt-/- mice had increased O2 consumption (Figure 4.2E), increased CO2 
release (Figure 4.2F) and increased heat production (Figure 4.2G) throughout the light and 
dark phases. Bhmt-/- mice were not hyperactive (Figure 4.2I), suggesting that the increase in 
metabolic rate was independent of activity. The respiratory exchange ratio (RER), an 
indicator of metabolic fuel preference, was significantly elevated in Bhmt-/- mice during the 
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light phase (and there was a trend of increasing RER during the dark phase), (Figure 4.2H), 
implying that Bhmt-/- mice may rely more on the oxidation of glucose and less on fatty acids, 
consistent with improved insulin sensitivity and glucose tolerance. 
 
Thermogenesis Was Not Increased in Bhmt-/- Mice – We next investigated whether the 
reduced adiposity observed in Bhmt-/- mice was due to increased thermogenesis. We 
predicted that Bhmt-/- mice would maintain a higher body temperature during a cold 
challenge if they had increased thermogenesis. After 6 hours of cold exposure, the wildtype 
controls dropped body temperature by 7.4% (from 38.18 ± 0.14 ºC to 35.36 ± 0.07 ºC), while 
Bhmt-/- mice dropped body temperature by 28.9% (from 37.92 ± 0.09 ºC to 26.98 ± 2.15 ºC) 
(Figure 4.3A). Mice were removed from the cold room when body temperature was less than 
28 ºC. Brown adipose tissue (BAT) is a major site of nonshivering adaptive thermogenesis. 
We found no significant difference in the morphology or the weight of interscapular BAT 
between wildtype and knockout mice (data not shown). Real-time PCR analysis revealed 
normal thermogenic gene responses in Bhmt-/- BAT tissue during cold exposure, with 
elevated Pgc1 (peroxisome proliferator activated receptor γ coactivator), Lpl (lipoprotein 
lipase), Ucp1 (uncoupling protein 1), and Mcpt1 (muscle-type carnitine palmitoyltransferase 
1) expression levels similar to those of Bhmt+/+ mice (Figure 4.3B), indicating that the 
adrenergic signaling was intact and similar between genotypes. Bhmt+/+ and Bhmt-/- mice had 
similar BAT TAG concentration before and after cold exposure, suggesting similar fuel 
storage and usage (Figure 4.3C). Mice were also able to maintain body temperature using 
exogenous fuels derived from organs such as white adipose tissue and liver, and through 
adaptive thermogenesis involving shivering in skeletal muscle to increase energy output. 
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Upon cold exposure, Bhmt-/- mice had significantly lower plasma glucose (by 46%), glycerol 
(by 46%), and NEFA (by 17%) concentrations compared to those of wildtype controls 
(Figure 4.3D-F), suggesting a restricted supply of exogenous fuels. Bhmt-/- mice also had a 
significantly elevated plasma creatine kinase activity (by 1.76 fold), a marker for muscle 
breakdown, perhaps because of increased shivering (Figure 4.3G).     
 
BHMT Deficiency Resulted in Altered Clinical Measurements in Plasma - We examined 
whether genotypic differences in energy balance were accompanied by changes in plasma 
clinical measurements. Basal plasma glycerol, NEFA, glucose, and TAG concentrations were 
similar for the two genotypes (Figure 4.3D-4.3F) as previously published [226]. Basal 
plasma insulin concentration was 50% lower in Bhmt-/- mice than in controls (p<0.05) (Table 
4.1). Because of the prominent role of thyroid hormone in controlling metabolic rate, we 
investigated whether increased thyroid hormone concentration contributed to the 
hypermetabolic phenotype in Bhmt-/- mice. Indeed, Bhmt-/- mice had a 33% increase in 
plasma T4 (the major form of thyroid hormone in blood) concentration compared to that of 
wildtype controls (p<0.05). Concentration of fibroblast growth factor 21 (FGF21), a recently 
discovered metabolic and glucose regulator, was found to be 1.75-fold higher in Bhmt-/- 
plasma than in Bhmt+/+ plasma (p<0.01). The increase in plasma FGF21 concentration 
observed in Bhmt-/- mice was accompanied by a 3.35-fold increase in hepatic Fgf21 
expression (where FGF21 is predominantly produced) compared to that of Bhmt+/+ mice 
(p<0.05). Growth hormone and T3 concentrations were not different between genotypes. 
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BHMT Deficiency Resulted in Increased Bile Acids in Liver and Adipose Tissue – A 
novel concept indicating a signaling role of bile acids (BAs) in the control of energy 
metabolism has emerged [132, 133]. Increasing BA pool size in mice increased energy 
expenditure [133], while decreasing BA pool size reduced energy expenditure, resulting in 
weight gain and insulin resistance [132]. Since Bhmt-/- mice had reduced plasma cholesterol 
(the precursor of BAs) [226], we investigated whether Bhmt deletion altered the 
concentrations of BAs. Cholic acid and chenodeoxycholic acid are the primary BAs and 
often conjugated with taurine (as taurocholate or taurochenodeoxycholate) or glycine (as 
glycocholate or glycochenodeoxycholate) forming bile salts. Compared to wildtype 
littermates, Bhmt deletion resulted in 9.50-fold and 3.41-fold increases respectively in cholate 
(p<0.01) and taurocholate (p<0.05) in adipose tissue, and in 2.33-fold and 1.62-fold increases 
respectively in taurocholate (p<0.05) and glycocholate (p<0.01) in liver (Table 4.2). 
Cholesterol is hydrolyzed to form 7 hydroxycholesterol, the precursor of bile acids. 
Compared to the controls, Bhmt-/- mice had reduced cholesterol (by 20%, p<0.05) and 
increased 7-β-hydroxycholesterol (by 2.98-fold, p<0.05) concentrations in the liver, and 
increased 7-α-hydroxycholesterol (by 2.17-fold, p<0.01) concentrations in the adipose tissue. 
These data suggested that Bhmt deletion enhanced the synthesis of bile acids from cholesterol, 
and that the bile acids may contribute to the increased energy expenditure observed in Bhmt-/- 
mice.      
 
BHMT Deficiency Resulted in Reduced Cellular ATP/AMP Ratio in Liver But Not in 
Adipose Tissues, and in Reduced Hepatic Glucose and Glycogen – Because Bhmt-/- mice 
displayed signs of lipodystrophy (fatty liver [226] and reduced fat pads), we measured ATP 
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and AMP in these organs (Table 4.1). Bhmt+/+ and Bhmt-/- mice had the same energy levels 
(ATP, AMP, ATP/AMP) in both GWAT and IWAT. However, in the liver, where Bhmt is 
predominantly expressed, Bhmt-/- mice had a reduced ATP/AMP level (by 65.7%, p<0.05) 
compared to Bhmt+/+ mice. The reduced ATP/AMP ratio was due to a 42% reduction in ATP 
concentration and a 61% increase in AMP concentration in Bhmt-/- liver compared to those of 
Bhmt+/+ liver (p<0.05). The reduced ATP/AMP ratio in Bhmt-/- liver was not due to decreased 
mitochondria content as there was no difference in mitochondria DNA in liver between 
wildtype and knockout mice. Bhmt-/- mice had reduced hepatic glucose (by 22% at 5 weeks 
of age and by 53% at 48 weeks of age) and glycogen (by 17% at 5 weeks of age and by 87% 
at 48 weeks of age) concentrations compared to those of Bhmt+/+ mice (Table 4.1). These 
data indicated that Bhmt-/- mice might be oxidizing more glucose (hence not storing them as 
glycogen), perhaps in an attempt to maintain the cellular ATP/AMP level. These data were 
consistent with the increased RER in Bhmt-/- mice, and perhaps explained why these mice 
were cold intolerant (due to lack of external glucose fuel).   
 
Bhmt-/- Mice Did Not Have Altered Lipolytic Rate – To investigate whether the markedly 
decreased adiposity observed in Bhmt-/- mice was due to increased lipolysis, we measured 
lipolytic rate in both in vivo and ex vivo models whereby lipolytic stimuli were given, and 
glycerol released was measured as the indicator of lipolytic rate. Plasma TAG and glucose 
were also measured in the in vivo model to determine the whole-body response to adrenergic 
stimuli. During the in vivo experiment, when CL316243 (β3 adrenergic specific lipolytic 
stimulus) was administered, Bhmt+/+ and Bhmt-/- mice had similar levels of plasma TAG, 
glycerol, and glucose release (Figure 4.4A-C). When isoproterenol (non-specific lipolytic 
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stimulus) was administered, Bhmt+/+ and Bhmt-/- mice had similar levels of plasma TAG and 
glycerol (Figure 4.4A-B), but a 50% decreased plasma glucose concentration compared to 
wildtype controls (Figure 4.4C). Lipolysis was further analyzed in isolated GWAT and 
IWAT explants from Bhmt+/+ and Bhmt-/- mice. The explants from Bhmt-/- mice released 
similar amounts of glycerol as did those from Bhmt+/+ mice under basal or stimulated 
conditions (Figure 4.4D-E), suggesting normal lipolytic machinery in Bhmt-/- mice. 
 
BHMT Deficiency Resulted in Impaired TAG Synthesis and Enhanced Glucose 
Oxidation in Isolated Mature Adipocytes – Since TAG breakdown was not defective, we 
assessed whether TAG synthesis and FA oxidation were altered within the fat cells. We 
isolated mature adipocytes from both GWAT and IWAT from Bhmt-/- mice and their 
littermate controls and measured the rates of [1-14C]oleate incorporation into TAG (for TAG 
synthesis), into CO2 (for complete FA oxidation) and acid soluble metabolites (for 
incomplete FA oxidation). Mature adipocytes isolated from Bhmt+/+ and Bhmt-/- GWAT had 
the same rate of TAG synthesis (Figure 4.4F). Interestingly, mature adipocytes isolated from 
Bhmt-/- IWAT made less TAG (by 62%) compared to that of Bhmt+/+ mice (p<0.001). GWAT 
and IWAT adipocytes from Bhmt+/+ and Bhmt-/- mice had the same FA oxidation rate (Figure 
4.4G), indicating normal β oxidation machinery. Since several lines of evidence (RER, 
enhanced glucose tolerance and insulin sensitivity, reduced glucose upon cold exposure and 
isoproterenol stimulus, reduced hepatic glucose and glycogen concentrations) suggested an 
increased reliance on glucose in Bhmt-/- mice, we assessed whether their mature adipocytes 
used more glucose. At basal level (without insulin), mature adipocytes isolated from Bhmt+/+ 
and Bhmt-/- GWAT had the same glucose oxidation rate (Figure 4.4H). However, with 
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insulin treatment, Bhmt-/- GWAT oxidized 2.38-fold more glucose than did Bhmt+/+ GWAT 
(p<0.05). Mature adipocytes isolated from Bhmt-/- IWAT oxidized 2.4-fold and 1.78-fold 
more glucose than did Bhmt+/+ IWAT without and with insulin treatment (Figure 4.4I). 
Compared to basal level, insulin treatment induced glucose oxidation by 1.87-fold, 4.17-fold, 
3.21-fold, and 3.79-fold respectively for Bhmt+/+ GWAT, Bhmt-/- GWAT, Bhmt+/+ IWAT, 
and Bhmt-/- IWAT, confirming the viability of the isolated mature adipocytes, and indicating 
a higher response to insulin in Bhmt-/- mice, particularly in GWAT (Figure 4.4H, 4.4I).  
 
4.5 DISCUSSION 
 
BHMT is one of the most abundant proteins in the liver, representing 0.6-1.6% of the 
total protein [43]. However, its known functions are limited to its roles in choline and one-
carbon metabolism. Our current studies establish a unique role for BHMT in energy 
homeostasis. These findings are remarkable given that these mice had reduced adiposity and 
better insulin sensitivity and glucose tolerance when fed a diet containing 5% fat. 
 
Previously, we found that Bhmt-/- mice had reduced body weight from 5 to 9 weeks of 
age compared to wildtype littermates, although the difference in body weight disappeared 
after 9 weeks [226]. MRI and dissection of fat pads revealed that the reduced body weight in 
Bhmt-/- mice was due to lower fat mass. Different from changes in body weight, Bhmt-/- mice 
had fat pad mass smaller up to 1 year of age compared to the controls. Bhmt-/- mice were able 
to maintain body weight in light of the reduced fat mass perhaps due to the fact that they had 
heavier liver (fatty liver and liver tumor) that made up the difference in weights [226]. 
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BHMT is a liver-specific enzyme in rodents [18]. Since BHMT protein is absent in normal 
adipose tissue, this observation indicates that the reduced fat mass in Bhmt-/- mice was due to 
an indirect effect of the lack of hepatic BHMT activity. How could lack of a hepatic enzyme 
result in reduced fat mass? One possibility is diminished lipid transport from the liver to 
adipose tissue via very low density lipoprotein (VLDL). Our previous work showed that 
Bhmt-/- mice had reduced hepatic PtdCho concentration, resulting in decreased VLDL 
secretion and increased hepatic fat accumulation [226]. However, the amount of fat missing 
in fat pads exceeds the excess amount accumulated in the liver. In addition, adipose should 
be able to store lipid obtained from the diet instead of depending solely on hepatic lipid 
sources. Thus, decreased VLDL secretion is unlikely to account for all the fat absence. 
Homeostasis of energy stores is regulated by mechanisms that include modulation of 
metabolic rate and thermogenesis, control of metabolite fluxes among various organs, and 
modulation of fuel synthesis and usage within adipose tissue. Examination of each of these 
parameters in Bhmt-/- mice showed that multiple factors might contribute to the reduced 
adiposity observed in this mouse model. 
 
Bhmt-/- mice had normal food intake, fat clearance rate, and fecal fat content, 
indicating that the reduced adiposity was not due to reduced energy intake or fat 
malabsorption. Bhmt-/- mice had increased rates of O2 consumption, CO2 release, and heat 
production, suggesting that the reduced fat mass was partially due to hypermetabolism. 
Because locomotor activity did not differ between genotypes, the increased energy 
expenditure exhibited by Bhmt-/- mice was not due to increased physical activity. The 
increased RER suggested that Bhmt-/- mice were oxidizing more glucose, instead of FA, as 
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fuel to maintain whole body metabolism, particularly during the fasting period. We 
investigated whether the reduced adiposity was due to increased thermogenesis. Upon cold 
exposure, Bhmt-/- mice failed to maintain their body temperature. Bhmt-/- mice exhibited 
normal induction of genes involved in mitochondrial biogenesis, uncoupling, and fatty acid 
oxidation in BAT. Furthermore, Bhmt-/- mice had normal BAT TAG storage and functional 
lipolytic machinery in peripheral tissues. However, during prolonged cold exposure, Bhmt-/- 
mice had lower plasma glucose, glycerol, and NEFA and higher plasma CK (marker of 
muscle breakdown). These data indicate that Bhmt-/- mice were not hyperthermogenic. In fact, 
these animals were cold sensitive due to lack of exogenous fuel, and had to depend on 
shivering thermogenesis in an attempt to maintain body temperature. The reduced plasma 
glucose in Bhmt-/- mice during cold exposure was probably because they had less glucose and 
glycogen stored in the liver or increased demand of glucose as fuel supply. The reduced 
plasma glycerol and NEFA in Bhmt-/- mice during cold exposure was probably because they 
had less TAG stored in the adipose tissue to be released during energy needs. It was also 
possible that Bhmt-/- mouse liver was taking up glycerol and NEFA more efficiently for 
synthesizing glucose to make up the lack of glucose and glycogen stores. 
 
Within the adipose tissue, we observed that Bhmt-/- IWAT, but not GWAT, made 62% 
less TAG than did the controls. Although Bhmt-/- had normal lipolytic and FA oxidation 
machinery in both fat depots, the mice might have less TAG stored at a time when fuel was 
needed. On the other hand, the energy level (ATP/AMP) in GWAT and IWAT did not differ 
for the two genotypes. These data together suggest that Bhmt-/- mice may be utilizing more 
glucose instead of FA to maintain the cellular ATP/AMP ratio. Indeed, we observed 
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increased glucose oxidation in Bhmt-/- GWAT with insulin stimulus, and increased glucose 
oxidation in Bhmt-/- IWAT with or without insulin stimulus. This hypothesis was further 
supported by the elevated RER obtained from the indirect calorimetry, the enhanced glucose 
and insulin sensitivities observed in Bhmt-/- mice, the reduced plasma glucose during cold 
exposure and ß-adrenergic stimulation, and the reduced hepatic glucose and glycogen 
concentrations. These data also suggest that the altered glucose metabolism in Bhmt-/- mice 
was not limited to adipose tissue, but also occurred in the liver. Enhanced whole-body 
glucose oxidation could limit the availability of acetyl-CoA forming fatty acids and the 
availability of the glycerol backbone forming TAG.    
 
It is intriguing that the observed effects were more pronounced in IWAT as compared 
to GWAT in Bhmt-/- mice. The size of Bhmt-/- GWAT adipocytes was 57% that of controls, 
while IWAT adipocytes size was 20% the size of that in controls. Adipocytes from Bhmt-/- 
IWAT synthesized 62% less TAG and oxidized 2.4-fold more glucose than did control 
IWAT, while no changes were detected in adipocytes from GWAT. It is commonly accepted 
that visceral (GWAT) and subcutaneous (IWAT) fat pads are different. GWAT is considered 
to be the “pure WAT”, while IWAT is a “convertible WAT” that may convert to BAT [237]. 
Compared to visceral fat, subcutaneous fat cells express more thyroid hormone receptors 
[238] and mitochondrial Ucp1 [239, 240], have more efficient insulin signaling and Glut4 
[241], and is more responsive to Pparγ thiazolidinedione ligand [242, 243]. When 
subcutaneous fat was transplanted into visceral cavity of mice, it reduced body weight and fat 
mass, and enhanced insulin and glucose sensitivities [244], suggesting an intrinsic difference 
between the two fat pads. These differences in GWAT and IWAT may explain why effects in 
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Bhmt-/- IWAT are more pronounced. Similar findings have been observed in a different 
mouse model [245].    
 
Bhmt-/- mice had reduced adiposity due to increased energy expenditure, enhanced 
glucose oxidation, and reduced TAG synthesis (Figure 4.5). The next question was how 
Bhmt deficiency could exert these differences, and we identified several candidates that may 
be responsible. Coinciding with increased energy expenditure, Bhmt-/- mice had elevated 
plasma T4 (the major form of thyroid hormone in the blood), a well-known energy 
metabolism regulator. Bhmt-/- mice also over-expressed hepatic Fgf21 and plasma FGF21 
concentration was elevated, possibly contributing to the elevated energy expenditure and the 
enhanced glucose sensitivity. FGF21 is a novel metabolic regulator that is preferentially 
expressed in the liver [140]. FGF21 increases glucose uptake [142, 144] and decreased 
intracellular TAG content in adipocytes [144]; it lowers plasma glucose and TAG when 
administered to diabetic mice [142]; and it increases energy expenditure and improves insulin 
sensitivity in diet-induced obese mice [145, 146]. Furthermore, Bhmt-/- mice had increased 
bile acids concentrations in both liver and adipose tissue. Recent progress suggested a role of 
bile acids in glucose and energy homeostasis. Mice fed a cholic acid (a bile acid) 
supplemented diet had increased energy expenditure, preventing obesity and insulin 
resistance [133], while mice with reduced bile acids had decreased energy expenditure [132].  
Bhmt deletion resulted in increased cholate and taurocholate in adipose tissue, and in 
increased taurocholate and glycocholate in liver. Bhmt-/- mice had reduced hepatic and serum 
cholesterol [226]. This was perhaps due to an increased conversion of cholesterol to cholic 
acid. Indeed, the concentration of 7-hydroxycholesterol, the precursor to bile acid from 
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cholesterol, was significantly elevated in both liver and adipose in Bhmt-/- mice. A growing 
body of evidence suggested an interaction among bile acids, thyroid hormone and FGF21. 
Thyroid hormone induced cholesterol 7α hydroxylase (CYP7A1), the rate-limiting enzyme in 
bile-acid synthesis from cholesterol [138, 139], and there was an inverse relationship 
between thyroid hormone level and serum cholesterol [136]. Thyroid hormone also induced 
hepatic Fgf21 expression in mice [147].  Bile acids enhanced the conversion of T4 to T3 
within tissues, resulting in increased energy expenditure in mice [133]. Both bile acids and 
FGF21 concentrations were elevated in patients with nonalcoholic fatty liver [149]. Bile 
acids, thyroid hormone and FGF21 all induce similar metabolic changes, and these data 
together suggested that there was an interaction among these factors and Bhmt deficiency. All 
of these were altered in Bhmt-/- mice and could contribute to the reduced adiposity observed 
in Bhmt-/- mice. However, more studies are required to elucidate the interaction among these 
factors and their roles in reduced adiposity in Bhmt-/- mice. 
 
Aside from the increased bile acids, thyroid hormone and FGF21, deletion of hepatic 
Bhmt may cause reduced adiposity via changes in choline metabolites. As mentioned 
previously, BHMT is a major regulator of choline metabolism. Deletion of Bhmt resulted in 
altered choline metabolites, including a 21-fold and 2-fold increase in hepatic and adipose 
tissue betaine concentration and an 82% and 53% decrease in hepatic and adipose tissue 
choline concentration [226].  Recently, studies suggested that manipulation of dietary choline 
or alteration of pathways in choline metabolism may influence energy expenditure and 
adiposity. Mice fed a methionine and choline deficient diet (MCDD) were hypermetabolic, 
lost weight [150], and had better insulin sensitivity and glucose tolerance [154]. Mice with 
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the Pemt gene (making PtdCho from PtdEtn) deleted had normal metabolic parameters on a 
regular chow diet compared to wildtype controls, however, when fed a high fat diet, they had 
increased oxygen consumption and RER, accumulated less body fat and had increased 
glucose sensitivity [155]. The lack of weight gain in Pemt-/- mice disappeared when mice 
were supplemented with choline. These observations suggest a potential role of choline 
deficiency in modulating energy metabolism. Similar to MCCD fed mice and the Pemt-/- 
mice, Bhmt-/- mice had reduced choline and PtdCho concentrations, enhanced glucose and 
insulin sensitivities, increased energy expenditure and reduced adiposity.  
 
Bhmt ablation also resulted in a significant accumulation of betaine, which serves as a 
methyl donor and osmolyte. Betaine is commercially available as a feed additive; it is widely 
discussed as a “carcass modifier” due to its lipotropic and growth-promoting effects, 
generating leaner meat [156]. Dietary betaine supplementation resulted in reduced abdominal 
fat in poultry, and reduced carcass fat (by 10-18%) in pigs [156-181]. The exact mechanism 
by which betaine modulates carcass quality is still unclear but has been suggested to involve 
interactions of betaine with growth factors and thyroid hormones [172, 175, 179, 181, 187-
191]. We did not observe increased growth hormone, but did observe enhanced plasma T4 
and FGF21 concentration and consequently hypermetabolism in Bhmt-/- mice. Betaine may 
also have a role as a glucose sensitizer. Betaine supplementation enhanced insulin sensitivity 
in diet-induced-obese mice and increased insulin signaling pathway in isolated adipocytes 
[99].  
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To summarize (Figure 4.5), Bhmt deletion resulted in reduced adiposity, enhanced 
insulin sensitivity and glucose tolerance. The reduction in fat mass in Bhmt deficient mice 
could be attributed to (1) increased whole body energy expenditure (2) decreased 
mobilization of lipids from the liver (VLDL) to be stored in adipose tissues (3) decreased 
TAG synthesis within adipocytes, and (4) increased glucose oxidation. Deletion of Bhmt 
resulted in a panel of abnormalities, including elevated thyroid hormone, bile salts, FGF21, 
and betaine concentrations, and reduced choline and PtdCho concentrations. Many of these 
have been related to elevated energy metabolism, reduced adiposity, and enhanced glucose 
tolerance and insulin sensitivity. How these parameters interact with each other warrant 
further studies. This study suggests the importance of Bhmt in regulating energy metabolism 
and adiposity. 
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4.6 FIGURES 
 
Figure 4.1. Bhmt-/- mice have reduced adiposity and better insulin & glucose sensitivities. 
A. Body mass was measured in 14-week-old Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice 
using magnetic resonance image (MRI). *p<0.01, different from Bhmt+/+ mice by Students’ t 
test; n=6 per group. B. Two major fat pads, gonadal (GWAT) and inguinal (IWAT) white 
adipose tissues, were harvested from from Bhmt+/+ (black square) and Bhmt-/- (white square) 
mice at various age. *p<0.01, different from Bhmt+/+ of the same age by Students’ t test; 
n=10-16 per group for 5-12 week old mice and n=5 per group for 20-48 week old mice. C. 
Morphology of GWAT and IWAT from 3-month-old mice was shown by hematoxylin-eosin 
staining. Scale bar = 50 µm. D. The adipocyte cell area of GWAT and IWAT from Bhmt+/+ 
(black bar) and Bhmt-/- (white bar) mice was analyzed using Zeiss AxioVision software. 
*p<0.05, **p<0.01, different from Bhmt+/+ mice by Students’ t test; n=3-5 per group. E. 
BHMT protein in liver and adipose tissue from Bhmt+/+ and Bhmt-/- mice were probed by 
Western blot analysis. The size of BHMT protein is 45 kDa. F-G. Glucose tolerance test (F) 
and insulin tolerance test (G) was done in 7-week-old Bhmt+/+ (black square) and Bhmt-/- 
(white square) mice via intraperitonal injection of either glucose or insulin and measuring tail 
blood glucose at various time points. *p<0.05, different from Bhmt+/+ by Students’ t test; n=7 
per group. Data is presented as mean ± SEM. 
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Figure 4.2. Bhmt-/- mice have altered energy metabolism. A. Food intake was measured in 
7-week-old Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice using indirect calorimetry; n=8 
per group. B. A fat tolerance test was performed in 7-week-old Bhmt+/+ (black square) and 
Bhmt-/- (white square) mice via oral gavage of olive oil and measuring plasma TAG at 
various time points; n=3 per group. C. Fecal fat from Bhmt+/+ (black bar) and Bhmt-/- (white 
bar) mice was extracted and measured using a colorimetric assay; n=7 per group. D. Rectal 
temperature of 7-week-old Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice was measured 
using a rectal probe thermometer at room temperature; n=6-7 per group. E-I. Oxygen 
consumption (E), carbon dioxide release (F), heat release (G), respiratory exchange ratio 
(CO2 release/O2 used) (H), and locomotor activity (I) were measured in 7-week-old Bhmt+/+ 
(black) and Bhmt-/- (white) using indirect calorimetry. Data was obtained after mice being 
acclimated to the chambers for 24 hr. *p<0.05, **p<0.01, different from Bhmt+/+ mice by 
Students’ t test; n=8 per group. Data is presented as mean ± SEM. TAG, triacylglycerol; VO2, 
oxygen consumption; VCO2, carbon dioxide release; RER, respiratory exchange ratio. 
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Figure 4.3. Bhmt-/- mice are cold sensitive. Seven-week-old mice were exposed to room 
temperature or 4°C, and tissues collected after 6 hour exposure. A. Body temperature of 
Bhmt+/+ (black square) and Bhmt-/- (white square) mice exposed to 4°C was measured using a 
rectal probe thermometer at different time point. *p<0.05, **p<0.01, different from Bhmt+/+ 
mice at the same time point by Students’ t test; n=13-14 per group. B. Expression of genes 
involved in thermogenesis in the BAT of Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice at 
room temperature (n=3-4 per group) or 4°C (n=7-8 per group) exposure. C. TAG in BAT 
from room temperature (n=3-6 per group) or 4°C (n=13-14 per group) exposed Bhmt+/+ 
(black bar) and Bhmt-/- (white bar) mice were extracted and measured colorimetrically. D-G. 
Plasma glucose (D), glycerol (E), NEFA (F), and CK (G) from room temperature (n=3-6 per 
group) or 4°C (n=13-14 per group) exposed Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice 
were measured colorimetrically. *p<0.05, different from Bhmt+/+ mice under the same 
condition by Students’ t test. Data is presented as mean ± SEM. BAT, brown adipose tissue; 
NEFA, non-esterified fatty acid; CK, creatine kinase; PGC1α, pparγ coactivator 1α; LPL, 
lipoprotein lipase; UCP1, uncoupling protein 1; MCPT1, muscle carnitine palmitoyl 
transferase 1. 
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Figure 4.4. Bhmt-/- mice have altered TAG synthesis and glucose oxidation. A-C. Plasma 
TAG (A), glycerol (B), and glucose (C) were measured in 7-week-old Bhmt+/+ (black bar) 
and Bhmt-/- (white bar) mice before and after ip injection of lipolytic stimulus isoproterenol 
or CL316243; n= 5-7 per group. D-E. Gonadal (D) or inguinal (E) explants from Bhmt+/+ 
(black square) and Bhmt-/- (white square) mice were used to measure glycerol release without 
(solid line) or with (dashed line) 10 µM lipolytic stimulus isoproterenol; n=4-6 per group. F. 
Mature adipocytes were isolated from Bhmt+/+ (black bar) and Bhmt-/- (white bar) mice 
GWAT and IWAT and used to determine the rate of labeled fatty acid incorporated to 
triacylglycerol. **p<0.01, different from Bhmt+/+ mice by Students’ t test; n=4-5 per group. 
G. Mature adipocytes were isolated from Bhmt+/+ and Bhmt-/- mice GWAT and IWAT and 
used to determine the rate of 14C 18:1 oxidation: CO2 (grey bar), ASM (white bar); n=10-13 
per group. H-I. Mature adipocytes were isolated from Bhmt+/+ (black bar) and Bhmt-/- (white 
bar) mice GWAT (H) and IWAT (I) and used to determine the rate of glucose oxidation with 
or without insulin. *p<0.05,**p<0.01 different from Bhmt+/+ mice under the same treatment 
by Students’ t test; n=7-10 per group without insulin, n=4-7 per group with insulin. Data is 
presented as mean ± SEM. GWAT, gonadal white adipose tissue; IWAT, inguinal white 
adipose tissue; ASM, acid soluble metabolites; TAG, triacylglycerol; Iso, isoproterenol; CL, 
CL CL316243. 
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Figure 4.5. Overview of metabolic disturbances in Bhmt-/- mice. Increased energy 
expenditure, decreased lipid mobilization from the liver to adipose tissue, decreased TAG 
synthesis and enhanced glucose oxidation together resulted in reduced fat mass in Bhmt-/- 
mice. Bhmt deletion increased plasma FGF21 and T4 concentrations, and increased betaine 
and bile acids concentrations while decreased choline concentration in both liver and adipose 
tissue. All of these changes had been associated with increased energy expenditure, enhanced 
insulin sensitivity, and reduced adiposity, and might be interrelate with one-another. BHMT, 
betaine homocysteine S-methyltransferase; Cho, choline; Bet, betaine; PtdCho, 
phosphatidylcholine; VLDL, very low density lipoprotein; FA, fatty acid; TAG, 
triacylglycerol; FGF21, fibroblast growth factor 21; Chol, cholesterol; 7 hydroxychol, 7 
hydroxycholesterol; BAs, bile acids; Glu, glucose; Gly, glycogen; G-6-P, glucose-6-
phosphate; Dio2, deiodinase 2; T4, thyroxine; T3 triiodothyronine. 
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4.7 TABLES 
  
Table 4.1. Metabolites and Gene Expression of Bhmt+/+ and Bhmt-/- mice in Tissues. 
Plasma was collected from 7-12 week old Bhmt+/+ and Bhmt-/- mice after 4 h fasting, and 
metabolites measured using commercial available kits; n=8-17 per group. Liver, GWAT, 
IWAT were collected from 7-week-old Bhmt+/+ and Bhmt-/- mice unless otherwise indicated. 
Fgf21 expression and mitochondria DNA were measured by real-time PCR, and expressed 
relatively to the controls; n=6-10 per group. ATP and AMP were measured using a high 
pressure chromatography method; n=4 for ATP and AMP measurement. Glucose and 
glycogen were measured using an acid hydrolysis method; n=6 per group. *p<0.05, **p<0.01, 
different from Bhmt+/+ by Students’ t test. Data is presented as mean ± SEM. 
 
Organ Measurement Bhmt+/+ Bhmt-/- 
Plasma Insulin [ng/mL] 0.806 ± 0.120  0.405 ± 0.157*
 FGF21 [ng/mL] 1.49 ± 0.16  2.6 ± 0.3**
 T4 (thyroxine) [µg/dL] 4.61 ± 0.27  5.73 ± 0.22**
 T3 (triiodothyronine) [ng/dL] 69.92 ± 5.87  75.37 ± 9.87
 Growth hormone [ng/mL] 5.02 ± 1.23  4.66 ± 1.46
Liver FGF21 expression [arbitrary value] 1.00 ± 0.24  3.35 ± 0.95*
 Glucose [µmol/g liver] [5-wk-old] 23.22 ± 0.91  18.22 ± 1.47*
 Glucose [µmol/g liver] [48-wk-old] 24.35 ± 2.06  11.53 ± 2.39*
 Glycogen [µmol/g liver] [5-wk-old] 100.13 ± 7.01  83.13 ± 4.21
 Glycogen [µmol/g liver] [48-wk-old] 56.64 ± 15.31  7.22 ± 2.56*
 ATP [nmol/mg protein] 132.8 ± 14.8  77.0 ± 13.0*
 AMP [nmol/mg protein] 104.9 ± 30.6  169.2 ± 27.6
 ATP/AMP 1.49 ± 0.33  0.51 ± 0.17*
 Mitochondria DNA [arbitrary value] 1.00 ± 0.23  1.23 ± 0.21
GWAT ATP [nmol/mg protein] 74.6 ± 20.3  96.2 ± 28.4
 AMP [nmol/mg protein] 182.5 ± 28.2  220.8 ± 53.7
 ATP/AMP 0.50 ± 0.21  0.58 ± 0.31
 Mitochondria DNA [arbitrary value] 1.00 ± 0.08  1.26 ± 0.17
IWAT ATP [nmol/mg protein] 51.5 ± 7.8  66.8 ± 16.9
 AMP [nmol/mg protein] 226.8 ± 23.3  258.1 ± 12.1
 ATP/AMP 0.23 ± 0.04  0.25 ± 0.05
 Mitochondria DNA [arbitrary value] 1.00 ± 0.14  1.30 ± 0.11
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Table 4.2. Bile acids and sterols in Bhmt liver and adipose tissue. 
Liver and gonadal adipose tissue were collected from 5-week-old Bhmt+/+ and Bhmt-/- mice 
after 4 hour fasting; n=6 per group. The relative abundance of metabolites was measured and 
analyzed by liquid and gas chromatography by Metabolon (Research Triangle Park, NC). 
Dark grey=elevated relatively to controls, light grey=decreased relatively to controls, 
N/D=not-detected. 
 
METABOLITES LIVER
WT Mean KO Mean Fold 
Change 
P  
Value 
Cholate 0.84 ± 0.08 2.26 ± 0.78 2.71 0.184 
Taurocholate 0.75 ± 0.09 1.21 ± 0.12 1.62 0.010 
Glycocholate 0.88 ± 0.18 1.95 ± 0.43 2.33 0.021 
Taurochenodeoxycholate 1.62 ± 0.44 0.88 ± 0.22 0.54 0.228 
Cholesterol 1.19 ± 0.07 0.95 ± 0.06 0.80 0.036 
7-ß-hydroxycholesterol 0.76 ± 0.45 2.26 ± 0.71 2.98 0.020 
 ADIPOSE
 WT Mean KO Mean Fold 
Change 
P  
Value 
Cholate 0.94 ± 0.23 8.93 ± 2.88 9.50 0.005 
Taurocholate 1.14 ± 0.31 3.90 ± 0.96 3.41 0.020 
Cholesterol 1.09 ± 0.08 1.25 ± 0.10 1.15 0.261 
7-α-hydroxycholesterol 0.88 ± 0.19 1.92 ± 0.20 2.17 0.009 
7-ß-hydroxycholesterol 1.03 ± 0.18 1.53 ± 0.21 1.48 0.075 
   
 
 
 
  
 
 
 
 
 
CHAPTER V 
SYNTHESIS  
 
5.1 Overview  
 
This dissertation describes two independent projects that examine the metabolic 
consequences of Bhmt deficiency. In this work, we generated the first mouse model with the 
gene encoding Bhmt deleted. The results of these studies confirm the importance of BHMT 
in the regulation of homocysteine and one-carbon metabolism. The results of these studies 
also reveal that BHMT has broader metabolic effects than we previously anticipated. We 
show for the first time that BHMT is involved in hepatic carcinogenesis and in energy 
metabolism. Although many questions remain to be addressed, this work is expected to 
stimulate further research. This chapter will discuss the key findings from these projects and 
their future implications for understanding and treatment of BHMT-related diseases. 
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5.2 Bhmt deficiency caused hyperhomocysteinemia 
 
Elevation of Hcy has been associated with cardiovascular disease, neural tube defect, 
renal dysfunction, and cognitive impairment [43]. Although it is well established that BHMT 
functions to remethylate Hcy into methionine, this role has traditionally received little 
attention. This is due to the assumption that transsulfuration and methyl-folate pathways 
could potentially replace the lack of BHMT. Using Bhmt deficient mice, this dissertation 
provides compelling evidence that the role of BHMT in Hcy metabolism is not replaceable. 
Bhmt-/- mice have a substantial increase in hepatic (by 6-fold) and plasma Hcy (by 7.8-fold), 
suggesting that transsulfuration and methyl-folate pathways do not have the capacity to 
remove the excess Hcy due to Bhmt deficiency under normal conditions. 
 
BHMT and MS share the function of remethylating Hcy to methionine. MS uses 
methyl-folate as the methyl donor. An interesting question to ask is whether folate 
supplementation can reverse, while folate deficiency can exacerbate, the elevated plasma Hcy 
caused by Bhmt deletion? My student, Ignacio Cerdena, and I are currently addressing this 
question. We are feeding 6 week old Bhmt+/+ and Bhmt-/- female mice a folate deficient, a 
folate control or a folate supplemented diet for 4 weeks. We will collect plasma and tissues 
for analysis. Preliminary data from this study shows that Bhmt-/- mice have higher plasma 
homocysteine than do Bhmt+/+ mice in all dietary groups (Figure 5.1). The data also shows 
that a 4-week folate supplementation does not ameliorate the elevated plasma Hcy caused by 
Bhmt deficiency, while folate deficiency exacerbates it. This ongoing project provides a 
valuable message – humans who have HHcy due to BHMT deficiency may not benefit from 
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dietary folate supplementation, but they would do worse if they are not taking in enough 
folate. 
 
Figure 5.1 Plasma total homocysteine of Bhmt+/+ or Bhmt-/- mice on varying folate diets. 
Six weeks old Bhmt+/+ and Bhmt-/- mice were given a folate deficient, a folate control or a 
folate supplemented diet for four weeks. Plasma total homocysteine was quantified by high 
pressure liquid chromatography. Small letters, significantly different by diets within wildtype 
mice. Capitalized letters, significantly different by diets within knockout mice. *, 
significantly different by genotypes within the same diet. 
  
The pressing question arising from these findings is whether the elevated Hcy levels 
in Bhmt-/- mice affect the pathology of HHcy-related diseases, particularly cardiovascular 
diseases. Several mouse models of HHcy have been engineered to study the vascular 
pathophysiology of hyperhomocysteinemia [42]. Those include mice with the gene encoding 
Cbs, Mthfr or Mtr/Ms deleted [246-248]. Mice with homozygous defects in these genes have 
poor growth and survival, making the study of vascular pathophysiology of HHcy difficult 
[246-248]. Instead, studies have been done in mice with heterozygous defect in these genes. 
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These mice are barely hyperhomocysteinemic (plasma Hcy of 6-9 µM, compared with 3-5 
µM in wildtype littermates) and require additional diet manipulation to reach the HHcy state 
[249-251]. The Bhmt-/- mouse will be a valuable mouse model to examine the relationship 
between HHcy and vascular diseases because it survives to at least 1 year of age and is 
severely hyperhomocysteinemic. Future studies should examine whether deletion of Bhmt 
results in increased susceptibility to vascular diseases due to HHcy.  
 
5.3 Bhmt deficiency disturbed choline metabolites 
 
The results from this dissertation elucidate the effects of Bhmt deficiency on choline 
metabolites. As predicted, Bhmt deficiency results in a substantial accumulation of betaine in 
most tissues, except testis. Unexpectedly, Bhmt deficiency results in reduced choline and 
PtdCho concentrations in tissues, suggesting the complexity of the regulation of choline 
metabolism.  
 
Deletion of Bhmt does not result in accumulation of choline, the precursor of betaine. 
Choline is either oxidized to form betaine by the enzyme CHDH or used to form PtdCho. 
Since Bhmt-/- mice cannot use betaine, we expected to see product inhibition of CHDH, 
resulting in increased choline availability for use in PtdCho synthesis. The opposite has been 
observed, with lower choline and PtdCho concentrations in a number of tissues. Bhmt-/- mice 
have elevated hepatic Chdh expression and CHDH activity, suggesting that this gene is 
induced by some factor present in Bhmt-/- mice, possibly explaining increased use of choline 
to form betaine. It is intriguing that nature would sacrifice the possibility of synthesizing 
PtdCho to make methyl donors. This further demonstrates the importance of betaine and 
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AdoMet. The questions that arise from these findings regard how CHDH is regulated and 
whether it is differentially regulated based on tissue types. Testis is the only tissue that 
maintains normal betaine and choline concentrations during Bhmt deficiency. This finding 
suggests a rigid control of CHDH activity and the importance of maintaining choline 
metabolite homeostasis in the testis. Our laboratory finds that male mice with Chdh 
deficiency are infertile due to abnormal mitochondria in the testis [252]. Contrary to Bhmt-/- 
mice, Chdh-/- mice have high choline and low betaine concentrations, indicating a potential 
role of betaine in fertility. Amy Johnson in our laboratory is currently studying the role of 
Chdh in male infertility. Future studies examining the regulation of CHDH are needed to 
develop preventative strategies for male infertility.        
 
In addition to being a methyl donor, betaine also serves as an osmolyte that regulates 
cellular volume and fluid balance  [253]. Cells in the renal medulla are typically exposed to 
high extracellular osmolarity (NaCl and urea). High NaCl and urea cause water efflux from 
cells, resulting in reduced cellular volume and creating a hypertonic state that is damaging to 
cells [254]. Therefore, cells accumulate osmolytes such as betaine to counteract the 
hypertonicity by retaining water within cells. One would predict that betaine accumulation 
within renal cells would increase water retention, generating elevated urine osmolarity (lower 
urinary specific gravity). We observe the opposite, with Bhmt-/- mice have reduced urinary 
specific gravity. One possibility is that these mice are thirsty and consume extra fluid, 
leading to increased urinary output that consequently decreases urinary osmolarity. To test 
this hypothesis, fluid intake and urinary output need to be determined. Furthermore, within 
cells there are other organic osmolytes, such as glycerophosphocholine, taurine, sorbital, and 
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inositol. Whether betaine accumulation results in compensatory changes of other osmolytes 
remains to be answered. Future studies should examine the role of betaine in kidney function 
and betaine’s relationship with other osmolytes. 
 
The physiological consequences of accumulating excessive betaine within cells are 
not understood. Excessive levels of osmolytes could potentially result in cells swelling due to 
excess water retention and in altered intracellular ionic strength. The mitochondrion is the 
site of betaine formation (CHDH is a mitochondrial enzyme). Excess betaine accumulation 
and water retention could potentially result in swollen mitochondria, thereby altering 
oxidative and energy generating functions. This could potentially contribute to the altered 
energy metabolism and the fuel usage observed in Bhmt-/- mice. To examine the structure of 
organelles, various tissues from Bhmt mice have been collected and are now being processed 
for conducting transmission electron microscopy (TEM). If changes in organelles are 
observed, then cellular functions should be examined. It is essential for the future studies to 
examine the potential effects of betaine as an osmolyte in cellular functions.  
 
5.4 Bhmt deficiency altered hepatic health 
 
Alteration of one-carbon metabolism has been associated with liver diseases such as 
alcoholic and nonalcoholic fatty liver, human liver cirrhosis, and hepatocellular carcinoma 
for at least 50 years. Expression of genes involved in one-carbon metabolism, such as BHMT, 
is reduced significantly in human cirrhosis and hepatocellular carcinoma [255]. Betaine is 
used to treat both alcoholic and nonalcoholic fatty liver, while choline deficiency is the only 
nutrient deficiency that results in hepatocellular carcinoma (summarized in the background 
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section). Data from this dissertation demonstrates that Bhmt deficiency results in 
nonalcoholic fatty liver at an early age and hepatocellular carcinoma at 1 yr of age. Taken 
together, one-carbon metabolism plays a crucial role in hepatic health. However, the 
molecular bases of these findings are not fully elucidated.   
 
Bhmt-/- mice have a 6-fold increase in hepatic triacylglycerol concentration compared 
to their wildtype littermates. We show that Bhmt-/- mice have reduced hepatic PtdCho 
concentration (by 36%) and VLDL secretion, explaining the fatty liver. However, Bhmt may 
have more roles in hepatic lipid metabolism. Cultured hepatocytes overexpressing Bhmt, and 
rat livers following an in vivo induction of Bhmt, have increased apolipoprotein B expression, 
suggesting an additional role of betaine/BHMT system on lipoprotein homeostasis [101-103]. 
BHMT catalyzes the synthesis of methionine, which is the precursor of AdoMet. The cells 
need carnitine to transfer fatty acids to mitochondria, where fatty acid oxidation takes place. 
Carnitine is synthesized from lysine or methionine via methylation, in which AdoMet is 
required. Deletion of Bhmt could possibly reduce carnitine synthesis (by reducing methionine 
and AdoMet), resulting in limited fatty acid oxidation and a consequent fat accumulation in 
the liver. Fatty acid oxidation can be tested by incubating hepatocytes or liver homogenates 
with labeled fatty acid and collecting labeled CO2. This hypothesis probably does not apply 
to adipose tissue as Bhmt-/- mice have reduced fat mass and no change in fatty acid oxidation. 
 
Bhmt deficiency results in HHcy, which has been associated with altering several 
biological functions. HHcy has been shown to induce endoplasmic reticulum (ER) stress 
[108]. ER is an essential organelle, which provides a specialized environment for the 
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production and post-translational modifications of secretory and membrane proteins. Studies 
suggest that Hcy can be wrongly incorporated to proteins, causing protein misfolding and 
unfolding in the ER and increasing ER stress [93, 95, 101, 108]. Increased ER stress activates 
Srebp1c (sterol regulatory element binding protein 1c), an ER bound transcription factor that 
induces lipid synthesis, which further contributes to fatty liver. Transgenic mice 
overexpressing human BHMT are resistant to HHcy induced ER stress and are protected from 
alcohol induced fatty liver [95]. This hypothesis can be tested by measuring ER stress 
markers such as GRP78 (glucose regulated protein 78) and CHOP (C/EBP homologous 
protein) in tissue. HHcy is also associated with alteration in sterol metabolism. Mice with one 
allele of Mthfr deleted (Mthfr+/-, gene in the methyl-folate pathway) have HHcy and 
increased mRNA and protein levels of CYP7A1, an enzyme that mediates the synthesis of 
bile acids from cholesterol. Bhmt-/- mice have reduced cholesterol concentration in liver and 
increased bile acid concentrations in liver and adipose tissue. These data suggest that Bhmt 
deletion enhances the synthesis of bile acids from cholesterol. It is unclear whether HHcy in 
Bhmt-/- mice is the underlying mechanism for this phenotype.  
 
Bhmt deficiency may also result in oxidative stress. Oxidative stress plays a key role 
in the development of liver injury, and glutathione attenuates oxidative stress by scavenging 
free radicals. Glutathione (GSH) is made from cysteine, the synthesis of which requires 
AdoMet (Figure 2.4). GSH becomes glutathione disulfide (GSSG) when oxidized. The ratio 
of GSH and GSSG within a cell measures cellular toxicity. Since Bhmt deficiency reduces 
AdoMet by 50%, the synthesis of glutathione may be affected. Although we do not see a 
change in hepatic cysteine level in Bhmt-/- mice, plasma cysteine concentration is 
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significantly reduced during Bhmt deficiency. In addition, a side project looking at the 
metabolomics of Bhmt-/- mice reveals that Bhmt deficiency reduces both GSH and GSSG in 
the liver (Table 5.1). Compared to the controls, Bhmt-/- mice have reduced GSH (by 89%) 
and GSSG (by 20%) concentrations, leading to an 86% reduction in GSH:GSSG ratio. These 
data suggest that Bhmt-/- mice might be under cellular oxidative stress. The cellular stress 
may contribute to the later liver injury (fibrosis and HCC) observed in Bhmt-/- mice. The 
mitochondria are the primary intracellular site of oxygen consumption and the major source 
of reactive oxygen species. Glutathione maintains the redox balance in mitochondria. Future 
studies should examine how the reduced GSH:GSSG in Bhmt-/- mice affects the function of 
mitochondria, whose primary roles are to oxidize fuels and to generate ATP.  
 
Table 5.1 Glutathione Levels in Bhmt Mouse Liver 
 
 
Liver was collected from 5-week-old Bhmt+/+ and Bhmt-/- mice after 4 hour fasting; n=6 per 
group. The relative abundance of metabolites was measured and analyzed by liquid and gas 
chromatography by Metabolon (Research Triangle Park, NC). 
 
At 1 year of age, 64% of Bhmt-/- mice develop hepatic tumors. Histopathology 
confirms that these tumors are either hepatocellular adenomas or carcinomas. Even those 
samples that do not have visible tumors have a higher incidence of fat accumulation, cellular 
alteration and hyperplasia when compared to Bhmt+/+ livers. The pressing question arising 
 WT Mean KO Mean Fold Change P Value 
Glutathione, 
reduced (GSH) 
6.53 ± 2.62 0.71 ± 0.12 0.11 0.0184 
Glutathione, 
oxidized (GSSG) 
1.11 ± 0.02 0.88 ± 0.03 0.80 <0.001 
GSH:GSSG 5.95 ± 2.43 0.80 ± 0.13 0.14 <0.01 
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from these findings is the underlying mechanisms of Bhmt deletion in hepatocarcinogenesis. 
Understanding the role of BHMT in mitigating liver injury may help to develop effective and 
safe therapies for fatty liver diseases. Several mechanisms have been proposed linking 
choline deficiency to HCC (summarized in the background section). Those include increased 
lipid peroxidation, perturbed PKC pathway, and altered DNA methylation of genes involved 
in tumor genesis. We plan to investigate each of these hypotheses in ongoing work in our 
laboratory.  
 
To summarize, this dissertation shows that Bhmt deficiency results in adverse hepatic 
effects such as fatty liver and hepatocellular carcinoma. In the future studies, the metabolic 
basis of these findings needs to be addressed. In addition, the roles of Bhmt deficiency in ER 
stress, oxidative stress, apolipoprotein B synthesis, and sterol metabolism need to determined. 
 
5.5 Bhmt deficiency altered methylation potential 
 
Compared to wildtype mice, Bhmt-/- mice have a significant reduction in hepatic 
methylation potential (AdoMet:AdoHcy) - by 76% at 5 weeks of age, and by 91% at 1 year 
of age. Decreased hepatic AdoMet/AdoHcy could affect all methylation reactions, including 
the epigenetic modification DNA methylation. Alteration in DNA methylation may alter the 
expression of genes involved in tumor genesis, leading to altered cancer risks (summarized in 
the background section). Mat1A and Gnmt knockout mouse models are two examples with 
disturbed methyl group metabolism that leads to tumor genesis [121, 123].  
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To determine whether methyl group deficiency in Bhmt-/- mice results in altered DNA 
methylation pattern, and consequently, altered gene expression profile, I use CpG 
methylation and gene expression arrays. Bhmt-/- mice have a significant reduction in overall 
DNA methylation (Figure 5.2). However, when closely examining individual probes for 
CpG sites, no single CpG sites has been significantly different between genotypes with a 
false discovery rate less than 0.05. Several factors could contribute to this lack of finding: (1) 
a small N (n=5) per group, (2) variable methylation pattern within each group, particularly in 
the Bhmt-/- mice group, and (3) a lack of established bioinformatics methods specific for 
analyzing CpG arrays. To determine whether the methylation of a CpG site is altered, a 
methylation-specific-PCR or pyrosequencing for the particular CpG site may be better a 
approach. In conclusion, I believe there would be epigenetic effect due to Bhmt deficiency. 
However, I have failed to prove this using CpG methylation arrays. Future studies examining 
this question require better methods.  
 
 
  
 
Figure 5.2 Ratio between methylated and 
total DNA in Bhmt+/+ and Bhmt-/- mice. 
Genomic DNA was extracted from 5 week 
old Bhmt+/+ and Bhmt-/- mouse livers. A 
portion of the DNA was immunoprecipitated 
using an antibody specific against 5-
methylcytidine. The pulled-down methylated 
DNA and its own genomic DNA were labeled 
with cyanine (3 and 5 respectively) and 
cohybridized onto the CpG methylation array. 
Compared to the controls, Bhmt-/- mice had 
similar signal intensity for total genomic 
DNA, but less methylated DNA signal 
intensity. The data suggested that Bhmt-/- mice 
had DNA hypomethylation.  
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5.6 Bhmt deficiency altered fuel metabolism within adipocytes 
 
Bhmt-/- mice have smaller adipocytes in both gonadal and inguinal depots than do the 
controls. Factors that contribute to the size of an adipocyte include reduced lipid synthesis 
(FA and TAG synthesis) and increased lipid breakdown (lipolysis and FA oxidation). We 
show that Bhmt-/- mice have normal lipolytic and FA oxidation functions. In contrast, Bhmt-/- 
mice have reduced triacylglycerol synthesis in the isolated mature adipocytes from inguinal 
depots. These data suggest that the smaller adipocytes in Bhmt-/- mice are due to a problem in 
lipid synthesis rather than breakdown. However, this study does not define the mechanism by 
which Bhmt deletion reduces TAG synthesis. In addition, whether Bhmt deficiency results in 
reduced FA synthesis remains to be determined. Compared to the controls, Bhmt-/- mice 
oxidize more glucose in the whole body (by indirect calorimetry) and in the isolated 
adipocytes. Glucose undergoes glycolysis, generating pyruvate, which becomes the fatty acid 
precursor acetyl CoA. Increased glucose oxidation in Bhmt-/- mice may result in reduced 
acetyl CoA available for the synthesis of FA that is subsequently incorporated into TAG. 
Increased glucose oxidation in Bhmt-/- mice may also result in reduced glucose available in 
the adipose tissue for generating glycerol-3-phosphate, the glucose backbone required for 
TAG synthesis. To confirm the rate of FA synthesis, the incorporation of radiolabeled acetate 
or glucose into lipid can be measured in isolated primary adipocytes from Bhmt mice. To 
confirm the rate of glucose incorporation to lipid, glucose can be given to mice intravenously, 
and tissues collected for lipid extraction.  
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This study also does not determine the rate of adipocyte differentiation. The histology 
of both gonadal and inguinal fat pads shows that Bhmt-/- mice have a larger number of smaller 
adipocytes, so it is assumed that the reduced adiposity in Bhmt-/- mice is more likely due to 
problems in making or storing lipids, rather than problems in adipocyte differentiation. To 
study adipocyte differentiation, I have attempted to isolate and differentiate preadipocytes 
from Bhmt mice. However, Bhmt-/- mice have small fat pads, making preadipocyte isolation 
exceedingly difficult. In addition, the differentiation rate varies significantly from sample to 
sample such that I have failed to draw any reliable conclusions.  
 
This study has identified the possible metabolic bases that contribute to the reduced 
adiposity in Bhmt-/- mice, such as reduced TAG synthesis and increased glucose oxidation. 
Future studies need to investigate the direct links between Bhmt deletion and these changes. 
The FA synthesis rate and adipocyte differentiation in Bhmt mice may also need to be 
determined.  
 
5.7 Bhmt deficiency altered glucose metabolism 
 
Many lines of evidence from this study suggest that Bhmt deficiency alters glucose 
metabolism. Indirect calorimetry shows that Bhmt-/- mice oxidizes more glucose than fatty 
acids in the whole body system. Adipocytes isolated from Bhmt-/- mice oxidize more glucose 
than do those from Bhmt+/+ mice. We do not examine the underlying mechanisms of such 
findings. Is the increased glucose oxidation in Bhmt-/- mice caused by increased glucose 
uptake by tissues? Future studies should examine the uptake of labeled glucose into tissues. 
In addition, glucose metabolism in other tissues in these mice, particularly the liver, has not 
 119 
 
been closely investigated. Bhmt-/- mice have reduced hepatic glucose concentration and 
glycogen storage, which is assumed to be the consequence of an increased demand of 
glucose. However, I have not tested whether the reduced glycogen in Bhmt-/- mice is due to 
decreased glycogen synthesis from glucose or increased glycogen breakdown to release 
glucose.  
 
Whether or not Bhmt deficiency alters glucose metabolism via altering the insulin 
signaling pathway remains to be examined. Insulin binds to the insulin receptor (IR), which 
recruits insulin receptor substrates (IRS). IRS activates the PKB/Akt pathway, resulting in 
inhibition of gluconeogenesis and induction of glycogen synthesis. Several studies provide 
evidence that betaine/BHMT is associated with altered insulin homeostasis. A study 
demonstrates that betaine supplementation alleviates insulin resistance in high-fat-fed mouse 
model by activating Akt and ERK, two major kinases in the insulin signaling pathway, in the 
adipose tissues [99].  Another study demonstrates that betaine treatment enhances hepatic 
insulin signaling in high-fat-fed mouse model by activating hepatic IRS1, leading to 
enhanced glycogen synthesis [98]. Zucker diabetic fatty rats (model for type 2 diabetes) [256] 
and streprozotocin-diabetic rats (model of type 1 diabetes) [257] both have increased hepatic 
BHMT activity and Bhmt mRNA levels, implying a correlation between BHMT and insulin 
sensitivity. These studies, together with the evidence from this dissertation, suggest a role of 
betaine and BHMT in insulin signaling and glucose metabolism. The insulin-signaling 
pathway in both Bhmt-/- liver and adipose tissue requires additional attention. I have 
preliminary data showing that Bhmt-/- mice have increased protein levels of hepatic insulin 
receptors (Figure 5.3). Increased insulin receptors are often associated with increased 
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glycogen synthesis, which does not seem to be the case in Bhmt-/- mice. However, it is 
possible that the increased protein levels of hepatic insulin receptors are responses to the 
reduced hepatic glucose and glycogen concentrations observed in Bhmt-/- mice. The exact 
interaction between betaine/BHMT and insulin and glucose metabolism requires additional 
study.  
 
Future studies need to investigate the roles of betaine/BHMT in insulin and glucose 
homeostasis in closer detail. Does the Bhmt-/- mouse liver take up more glucose? Does the 
Bhmt-/- mouse have altered insulin signaling pathway? Why does the Bhmt-/- mouse have less 
glucose and glycogen stored in the liver? 
 
 
  
 
 
 
 
 
  
Figure 5.3 Insulin receptor (IR) α 
and ß in Bhmt mouse liver. Livers 
were collected from 7 week old 
Bhmt+/+ and Bhmt-/- mice. Insulin 
receptor α and ß protein levels were 
quantified using a Western blotting 
analysis. Bhmt-/- mice expressed 
higher hepatic insulin receptor 
protein than did Bhmt+/+ mice. 
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5.8 Bhmt deficiency increased energy expenditure 
 
Bhmt-/- mice have reduced adiposity in part due to increased energy expenditure. 
Although we have not identified a direct relationship between Bhmt deficiency and energy 
expenditure, we find several factors that could contribute to this phenotype. These factors 
include bile acids, FGF21, thyroid hormone, betaine and choline (summarized in the 
background section). All of these are altered in Bhmt-/- mice, and there seem to be an 
interaction among these factors. The question for future study is to identify which one of 
these is the key element to the reduced adiposity observed in Bhmt-/- mice? To answer this, 
one could alter one of these elements in Bhmt-/- mice and see if the alteration reverses the 
reduced adiposity. For example, one can feed Bhmt-/- mice a high choline diet to determine 
whether it can reverse the phenotype, under the assumption that Bhmt-/- mice will not use all 
choline to make betaine. One could inhibit CYP7A1, the enzyme that synthesizes bile acids 
from cholesterol to determine whether reduced bile acids can reverse this phenotype, under 
the assumption that reduced bile acids will not kill the mice. Figuring out how to moderately 
change one of these elements at a time remains a challenge finding the underlying 
mechanism of the reduced adiposity in Bhmt-/- mice. Another goal for future studies is to find 
the interactions among these factors. As discussed in the background section, thyroid 
hormone can induce the synthesis of bile acids and FGF21. Bile acids can transform 
prohormone T4 to the active thyroid hormone T3. Both bile acids and FGF21 concentrations 
increase in patients with nonalcoholic fatty liver disease. Future studies need to examine the 
underlying mechanisms of how Bhmt deletion alters the concentrations of these molecules, 
and how they interrelate with one another. 
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5.9 Are Bhmt-/- mice resistant to a high fat diet? 
 
Bhmt-/- mice have reduced body fat when fed a regular diet. However, it remains a 
question whether Bhmt deficiency are protected from diet-induced obesity. It is possible that 
a high-fat diet could override the increased energy expenditure and glucose oxidation in 
Bhmt-/- mice. This would be important to discover, since many Americans are facing an 
obesity problem due to the high-fat Western diets. 
 
5.10 Public Health Significance 
 
Elevated plasma total homocysteine in humans is associated with numerous diseases, 
particularly cardiovascular disease. Nonalcoholic fatty liver disease affects around 20% of 
the general global population, around 50% of diabetic subjects, >50% of obese persons, and 
90% of morbidly obese persons [258]. It can progress to steatohepatitis (fatty inflammation), 
fibrosis (excessive fibrous tissue), cirrhosis (serious liver damage), and eventually hepatic 
tumor [259]. Liver cancer is among the most lethal cancers (five-year survival rates under 
14%) in the United States. About 20,000 Americans are estimated to die of liver cancer in 
2011 [111]. There has been a striking increase in the prevalence of obesity in the United 
States during the past 20 years [260]. About 33% U.S. adults are obese, and 17% (12.5 
million) of children and adolescents are obese [260]. The medical costs of obesity in the 
United States are staggering, estimated to be $147 billion dolor per year [260]. The data 
presented in this dissertation provide novel evidence the important roles of BHMT in 
homocysteine homeostasis, in hepatic health, and in energy metabolism. Humans who have 
BHMT SNPs that result in drastically reduced BHMT activity may at higher risk for 
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cardiovascular diseases and hepatocellular carcinoma, and may have decreased body fat. 
More importantly, this dissertation reveals novel insights into the potential roles of choline 
and betaine in regulating hepatic health and adiposity. Although future studies are warranted, 
dietary intake of choline and betaine may be potential candidates as treatments for these 
related diseases.  
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